Repeated introductions and intensive community transmission fueled a mumps virus outbreak in Washington State

Louise H. Moncla^{*1#}, Allison Black^{1,2#}, Chas DeBolt³, Misty Lang³, Nicholas R. Graff³, Ailyn C. Pérez-Osorio³, Nicola F. Müller¹, Dirk Haselow⁴, Scott Lindquist³, Trevor Bedford^{*1,2}

1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

2. Department of Epidemiology, University of Washington, Seattle, Washington, United States

3. Office of Communicable Disease Epidemiology, Washington State Department of Health, Shoreline, Washington, United States

4. Arkansas Department of Health, Little Rock, Arkansas, United States

# these authors contributed equally to this work

* corresponding author; lhmoncla@gmail.com and trevor@bedford.io

Abstract

In 2016/2017, Washington State experienced a mumps outbreak despite high childhood vaccination rates, with cases more frequently detected among school-aged children and members of the Marshallese community. We sequenced 166 mumps virus genomes collected during outbreaks in Washington and other US states, and apply phylodynamic approaches to trace mumps introductions and transmission within Washington. We uncover that mumps was introduced into Washington at least 13 times, primarily from Arkansas, sparking multiple co-circulating transmission chains. Neither vaccination status nor age were strong determinants of

transmission. Instead, the outbreak in Washington was overwhelmingly sustained by transmission within the Marshallese community. Our findings underscore the utility of genomic data to clarify epidemiologic factors driving transmission, and pinpoint contact networks as critical determinants of mumps transmission. These results imply that contact structures and historic disparities may leave populations at increased risk for respiratory virus disease even when a vaccine is effective and widely used.

Introduction

In 2016 and 2017, mumps virus swept the United States in the country's largest outbreak since the pre-vaccine era (CDCMMWR, 2019). Washington State was heavily affected, reporting 889 confirmed and probable cases. Longitudinal studies (Davidkin et al., 2008), epidemiologic outbreak investigations (Cardemil et al., 2017), and epidemic models (Lewnard and Grad, 2018) suggest that mumps vaccine-induced immunity wanes over 13-30 years, consistent with the preponderance of young adult cases in recent outbreaks. Like with other recent mumps outbreaks, most Washington cases in 2016/17 were vaccinated. Unusually though, incidence was highest among children aged 10-18 years, younger than expected given waning immunity. The outbreak was also peculiar in that approximately 52% of the total cases were Marshallese, an ethnic community that comprises ~0.3% of Washington's population. These same phenomena were also observed in Arkansas. Of the 2,954 confirmed and probable Arkansas cases, 57% were Marshallese, and 57% of cases were children aged 5-17 (Fields et al., 2019). Amongst school-aged children in Arkansas and Washington, >90% had previously received 2 doses of MMR vaccine (Fields et al., 2019). The high proportion of vaccinated cases, younger-than-expected age at infection, disproportionate impact on the Marshallese community, and epidemiologic link to Arkansas suggest that factors beyond waning immunity are necessary to explain mumps transmission during this outbreak in Washington.

Between 1947 and 1986, the United States occupied the Republic of Marshall Islands and detonated the equivalent of >7000 Hiroshima size nuclear bombs as part of its nuclear testing program (Barker, 2012). The effects were devastating, precipitating widespread environmental destruction, nuclear contamination, and dire health consequences (Hallgren et al., 2015; Niedenthal, 1997; Palafox et al., 2007; Simon, 1997; Takahashi et al., 1997). Marshallese individuals inhabiting the targeted atolls were forcibly moved to other islands, and many were exposed to nuclear fallout (Abella et al., 2019) that persists on the Islands today (Bordner et al., 2016). Significant concern remains within the community regarding long-term health impacts of nuclear exposure and its potential impacts on immune function. Marshallese individuals living on and off the Islands experience significant health disparities including a higher burden from infectious diseases and chronic health conditions (Adams et al., 1986; Wong et al., 1979; Yamada et al., 2004). Compounding these disparities, from 1996 to 2020 (Hirono, 2019), Marshallese individuals were specifically excluded from Medicaid eligibility despite legal residency in the US permitted under the Compact of Free Association (COFA) Treaty. As a result, many US-residing Marshallese are uninsured, with poor access to healthcare (McElfish et al., 2015). Marshallese households also tend to be larger on average (Harris and Jones, 2005; US Census Bureau, n.d.), potentially increasing risk for respiratory virus exposure.

Sampling bias is a persistent challenge for elucidating source-sink dynamics during viral outbreaks. Here, we formulate a set of genomic epidemiological approaches that are robust to genomic sampling to investigate patterns of mumps transmission in Washington. We sequenced 110 mumps viral genomes obtained from specimens collected from laboratory-confirmed mumps cases in Washington State and another 56 from other US states collected between 2006 and 2018. We employ a novel application of phylogeographic methods to detailed

epidemiologic data on age, vaccination status, and community membership, and develop a new statistic for quantifying transmission in the tree. By combining these phylodynamic approaches with community health advocate interviews that contextualize our results, we provide a framework for investigating viral transmission dynamics that is sensitive to community health priorities and readily applicable to other viral pathogens.

Results

Figure 1: Washington case counts and genomic sampling

The first mumps case in Washington was reported on October 30, 2016, and case counts peaked in winter of 2017. The x-axis represents the date of the corresponding epidemiologic week, and the y-axis represents the number of confirmed and probable cases for that week. Blue dots above the case count plot represent the number of Washington genome sequences in our dataset sampled in that week.

Outbreak characteristics and dataset composition

We generated genome sequences for 110 PCR-positive mumps samples collected throughout Washington State during 2016/2017, and 56 samples collected in Wisconsin, Ohio, Missouri, Alabama, and North Carolina between 2006 and 2018 (**Supplemental Table 1**). The Washington State outbreak began in October 2016, and peaked in winter of 2017, culminating

in 889 confirmed and probable cases across Washington (**Fig. 1**). Individuals aged <1 to 64 years were affected, but the highest rate of infection occurred in children aged 10-14 (44.9 cases per 100,000) and 15-19 (47.0 per 100,000) (**Supplemental Table 2**). Among individuals aged 5-19 years old, 91% were considered up-to-date on mumps vaccine. Adults in the age group most likely to be parents of school aged children (20-39 years old) were infected at a rate of only 12.9 cases per 100,000, but comprised a significant proportion (29%) of total cases (**Supplemental Table 2**). While Marshallese individuals comprise only ~0.3% of Washington's total population, they accounted for 52% of reported mumps cases (**Supplemental Table 3**). Among Marshallese individuals aged 5-19, 93% were up-to-date on vaccination, suggesting that this over-representation is not attributable to poor vaccine coverage.

Outbreaks across North America are related

We combined our sequence data with publicly available full genome sequences sampled from North America between 2006 and 2018, and built a time-resolved phylogeny, inferring migration history among 26 US states and Canadian provinces (**Fig. 2, Supplemental Figure 1**). Sequences from samples collected between 2006 and 2014 clustered with other North American mumps viruses sampled from the same times. Except for 2 sequences (one from Wisconsin in 2006, genotype A, and one from Washington in 2017, genotype K, both excluded from **Fig. 2**), all samples in our dataset were genotype G viruses. Ten Washington sequences were highly divergent from other North American genotype G viruses, with a time to the most recent common ancestor (TMRCA) of ~22 years (**Fig. 2**). The remaining Washington sequences nest within the diversity of other North American viruses, and descend from the same mumps lineage that has circulated in North America since 2006 (**Fig. 2**). We observe substantial geographic mixing along the tree. While viruses from Massachusetts (dark green tips and branches) seeded outbreaks in the Northeast and Midwest, we also infer transmission from

Figure 2: North American mumps outbreaks are related

We combined all publicly available North American mumps genomes and built a time-resolved phylogeny. Here, we display the maximum clade credibility tree, where each color represents a unique US state or Canadian province and the x-axis represents the collection date (for tips), or the inferred time to the most recent common ancestors (for internal nodes). We inferred geographic history using a discrete trait model. The color of each internal node represents the posterior probability of the inferred geographic location, where increasingly grey tone represents decreasing probability.

119
120 Massachusetts to Texas, Louisiana, Alabama, and British Columbia. Despite the close
121 geographic proximity between British Columbia and Washington, most British Columbia
122 sequences form a distinct cluster on a long branch (**Fig. 2**), suggesting seeding from an
123 unsampled location. Although viruses from Washington are scattered throughout the phylogeny,
124 most cluster within a clade of viruses sampled in Arkansas (**Fig. 2**).

125

Mumps was introduced into Washington multiple independent times

Estimating the number and timing of viral introductions is important for estimating epidemiologic parameters and evaluating surveillance networks, but is challenging with case count data alone. The Washington Department of Health had identified a single potential index case in October of 2016. To determine whether the genomic data supported a single introduction, we separated each introduction inferred in the maximum clade credibility tree and plotted each as its own transmission chain (**Fig. 3a**). We then enumerated the number of transitions into Washington in each tree in the posterior set, and plotted the distribution of Washington introductions consistent with the phylogeny (**Fig. 3b**).

Figure 3: The mumps outbreak in Washington was seeded by approximately 13 introductions. We separated each introduction inferred on the maximum clade credibility tree (Figure 2) and plotted them independently. Large, colored dots represent the inferred geographic location that the Washington introduction was seeded from. Branches that extend earlier than July of 2016 are dotted to represent that transmission likely occurred via other, unsampled locations. For reference, the cumulative case counts

from Arkansas and Washington are plotted below. **b.** For each tree in the posterior set, we inferred the number of introductions into Washington. We plot the proportion of trees in the posterior set in which that number of introductions was inferred.

Genomic data show that mumps was introduced into Washington State approximately 13 independent times (95% highest posterior density, HPD: 12 - 15), from geographically disparate locations (**Fig. 3**). Nine sampled tips descend from long branches (~22 years), suggesting likely transmission from unsampled geographic locations. We infer introductions from Ontario and Missouri that each lead to 1-3 sampled cases (**Fig. 3b**), suggesting limited onward transmission following these introductions. In contrast, 4 introductions from Arkansas account for 92/110 sequenced cases, suggesting that these introductions led to more sustained chains of transmission following introduction (**Fig. 3b**). We refer to the largest cluster as the “primary outbreak clade,” and infer its introduction from Arkansas to Washington around August of 2016 (August 7, 2016, 95% HPD: July 11, 2016 to September 19, 2016, **Fig. 3b**), 3.5 months before Washington’s first reported case. These data reveal that what had appeared to be a single outbreak based on case surveillance data was in fact a series of multiple introductions, primarily from Arkansas, sparking overlapping and co-circulating transmission chains.

SH gene sequencing is insufficient for fine-grained geographic inference

Mumps virus surveillance and genotyping relies on the SH gene (Centers for Disease Control and Prevention, 2019a), a short, 316 bp gene that is simple and rapid to sequence. To determine whether SH gene sequencing would have produced similar results, we built a divergence tree using our set of North American full genomes (**Supplemental Figure 2a**), then truncated that data to include only SH gene sequences (**Supplemental Figure 2b**). Almost all North American SH genes were identical, resulting in a single, large polytomy (**Supplemental Figure 2b**). This indicates that SH sequences lack sufficient resolution to elucidate fine-grained

patterns of geographic spread, consistent with previous findings (Gouma et al., 2016; Wohl et al., 2020).

Quantifying differences in transmission patterns within Washington

In both Arkansas and Washington, Marshallese individuals comprised over 50% of mumps cases, despite accounting for a much lower proportion of the population in both states. Phylogenetic reconstruction links the outbreaks in Washington and Arkansas, placing most sampled mumps genomes in Washington as descendant from Arkansas. We sought to investigate how mumps transmission may have differed within Marshallese and non-Marshallese communities within the same outbreak. Phylogenetic trees reflect the transmission process and can be used to quantify differences in transmission patterns among population groups. If transmission rates were distinct between Marshallese and non-Marshallese mumps cases, we expect the following: 1. Sequences from the high-transmitting group should be more frequently detected upstream in transmission chains. 2. Introductions seeded into the high-transmitting group should result in larger and more diverse clades in the tree. 3. The internal nodes of the phylogeny should be predominantly composed by members of the high-transmitting group, while members of the low-transmitting group should primarily be found at terminal nodes.

Marshallese cases are enriched upstream in transmission chains

We developed a transmission metric to quantify whether Marshallese cases were enriched at the beginnings of successful transmission chains. We traverse the full genome divergence phylogeny (**Supplemental Figure 2a**) from root to tip. When we encounter a tip that lies on an internal node, we enumerate the number of tips that descend from its parent node. We then classify each tip in the phylogeny as either having descendants or not, and compare the

proportion of tips with and without descendants among groups (**Fig. 4a**, see Methods for more details). Given our sampling proportion (110 sequences/889 total cases, ~12%), we do not expect to have captured true parent/child infection pairs. Rather, we expect to have preferentially sampled long, successful transmission chains within the state. This allowed us to assess whether infections with particular attributes (community membership, vaccination status, age) are predictors for being upstream in these chains, and thus associated with sustained transmission. We evaluated the probability of having descendants in the tree as a function of vaccination status, age, and community status with logistic regression (see Methods for details and full model). Neither age nor vaccination status were significantly associated with the presence of downstream tips in the tree (**Table 1**). However, Marshallese cases were significantly more likely to have downstream descendants than non-Marshallese cases (odds ratio = 3.2, $p = 0.00725$, **Table 1**). While only 27% (14/52) of non-Marshallese tips were ancestral to downstream samples, 56% (32/57) of Marshallese tips had downstream descendants. These results suggest that community membership was a significant determinant of sustained transmission while controlling for vaccination status and age.

Table 1: Logistic regression results of probability that phylogeny nodes has descendants

Predictor variable	Estimated coefficient (standard error)	Odds ratio (95% CI)	p-value
Not up-to-date	-0.77 (0.69)	0.46 (0.11, 1.70)	0.26
Vaccination status unknown	0.79 (0.80)	2.21 (0.59, 9.20)	0.32
Age	-1.2 (1.44)	0.30 (0.016, 4.70)	0.41
Community status	1.17 (0.43)	3.21 (1.39, 7.69)	0.0073

We evaluated the impact of vaccination status, age, and community membership on the probability that the phylogenetic node had descendants in the tree. Coefficients represent the increase in log odds of having descendants for the given predictor variable. Coefficients were exponentiated to produce odds ratios. We evaluated the impacts of having an unknown vaccination status, having a vaccination status that is not up-to-date, and being Marshallese as binary predictor variables. Age was evaluated as a continuous variable normalized such that values fall between 0 and 1.

Longer transmission chains are associated with community status

In the absence of recombination, closely-linked infections will cluster together on the tree, while unrelated infections should fall disparately on the tree, forming multiple smaller clusters. We inferred the number of Washington-associated clades in the tree as a function of whether sampled infections came from Marshallese or non-Marshallese individuals. Using the full North American phylogeny, we removed all Washington sequences and separated them into viruses sampled from cases noted as Marshallese or non-Marshallese. Then, separately for each group, we added sequences back into the tree one by one, until all sequences for that group had been added. For each number of sequences, we performed 10 independent trials (see Methods for complete details), and at each step, enumerated the number of inferred Washington clusters in the phylogeny. For comparison, we also grouped tips by vaccination status and repeated this analysis.

For tips from non-Marshallese individuals, the number of inferred clusters increases linearly as tips are added to the tree (**Fig. 4b**). This suggests that these infections are not directly related, and are not part of sustained transmission chains (**Fig. 4b**). In contrast, the number of inferred clusters for Marshallese tips stabilizes after ~10 tips are added, even as almost 50 more sequences are added to the tree. This pattern likely arises because many Marshallese infections are part of the same long transmission chain, such that newly added tips nest within existing clusters. We do not observe similar differences among vaccination groups (**Supplemental Figure 3**). These findings are consistent with distinct patterns of transmission among Marshallese versus non-Marshallese cases: transmission among Marshallese individuals resulted in a small number of large clusters, while transmission among non-Marshallese individuals are generally the result of disparate introductions that generate shorter transmission chains.

Figure 4: Transmission chains are longer within the Marshallese community

a. A schematic for quantifying tips that lie “upstream” in transmission chains. For tips that lie on an internal node, i.e., have a branch length of zero, we infer the number of child tips that descend from that tip’s parental node. For each tip in the example tree, the number of descendants we would infer is annotated alongside it. All tips that have a nonzero branch length are annotated as having 0 descendants. We can then compare whether sequences of particular groups (here, blue vs. red) are more likely to have descendants in the tree via logistic regression. **b.** We separated all Washington tips and classified them into Marshallese and not Marshallese. We then performed a rarefaction analysis and plot the number of inferred Washington clusters (y-axis) as a function of the number of sequences included in the analysis (x-axis). Dark blue represents not Marshallese sequences, and light blue represents Marshallese sequences. Each dot represents the number of trials in which that number of clusters was inferred, and the solid line represents the mean across trials. **c.** The exploded tree as shown in Figure 3a is shown, but tips are now colored by whether they represent Marshallese or non-Marshallese cases. For reference, the number of Washington cases (y-axis) is plotted over time (x-axis), where bar color represents whether those cases were Marshallese or not.

We next separated each Washington introduction and colored each tip by community membership. Every introduction that was not seeded from Arkansas led to exclusively non-Marshallese infections, while introductions from Arkansas defined lineages that circulated for longer and were enriched with Marshallese tips (**Fig. 4c**). The primary outbreak clade is particularly enriched, containing 43 Marshallese tips and 26 non-Marshallese tips, hinting that transmission chains are longer when Marshallese cases are present in a cluster.

Mumps transmitted efficiently within the Marshallese community

Internal nodes on a phylogeny represent ancestors to subsequently sampled tips, while terminal nodes represent viral infections that did not give rise to sampled progeny. If the mumps outbreak were primarily sustained by transmission within one group, the backbone of the phylogeny and the majority of internal nodes should be inferred as circulating in that group. We selected the 4 introductions that contained both Marshallese and non-Marshallese tips (**Fig. 4c**, the 4 Arkansas introductions), and reconstructed ancestral states along the phylogeny and migration/transmission rates between Marshallese and non-Marshallese groups using a structured coalescent model.

74/88 internal nodes were inferred to circulate within the Marshallese community with posterior probability of at least 0.95 (**Fig. 5a, b**). Movement of a lineage from the Marshallese deme into the non-Marshallese deme subsequently caused the lineage to die out quickly (**Fig. 5a**, dark blue branches). This suggests that transmission was overwhelmingly maintained within the Marshallese community, and that infections seeded into the non-Marshallese community did not sustain prolonged transmission chains. We estimate substantially more transmission from Marshallese to non-Marshallese groups than the opposite: within the primary outbreak clade, we estimate 29 transmission events from Marshallese to non-Marshallese groups (95% HPD: 21, 37), and only 6 (95% HPD: 0, 14) from non-Marshallese to Marshallese groups (**Fig. 5d**). This strongly suggests that transmission predominantly occurred in one direction: transmission events leading to non-Marshallese infections usually died out, and did not typically re-seed circulation within the Marshallese community. These results hold true regardless of migration rate prior (**Supplemental Figure 4**).

Figure 5: The Washington outbreak was sustained by transmission in the Marshallese community

a. Using the 4 Washington clusters that had a mixture of Marshallese and non-Marshallese cases, we inferred phylogenies using a structured coalescent model. Each group of sequences shared a clock model, migration model, and substitution model, but each topology was inferred separately, allowing us to incorporate information from all 4 clusters into the migration estimation. For each cluster, the maximum clade credibility tree is shown, where the color of each internal node represents the posterior probability that the node is Marshallese. **b.** For each internal node shown in panel a, we plot the posterior probability of that node being Marshallese. Across all 4 clusters, 74 out of 88 internal nodes (84%) are inferred as Marshallese with a posterior probability of at least 0.95. **c.** The posterior distribution of the number of “jumps” or transmission events from Marshallese to not Marshallese (light blue) and not Marshallese to Marshallese (dark blue) inferred for the primary outbreak clade.

To ensure that our results were not driven by unequal sampling within the analyzed clades, we generated 3 datasets in which the number of Marshallese and non-Marshallese tips were subsampled to be equal. For each of these 3 subsampled datasets, we ran 3 independent chains under the same model described above. Chains converged for 2 of the 3 subsampled datasets. In the converged chains, we recover very similar tree topologies (**Supplemental Figure 5a**) with equivalent phylogenetic reconstructions of lineage circulation within Marshallese

and non-Marshallese demes. We also recovered maximum clade credibility trees in which the vast majority of the internal nodes are inferred to circulate within the Marshallese deme (**Supplemental Figure 5a,b**), confirming that our findings are robust to sampling, consistent with past observations of model performance (De Maio et al., 2015; Dudas et al., 2018; Vaughan et al., 2014).

The structured coalescent model requires both groups to be present in each cluster, excluding several small Washington introductions composed entirely of non-Marshallese tips (**Fig. 4c**). To account for this, we used all Washington genotype G sequences in our dataset and estimated a single tree using an approximate structured coalescent model (Müller et al., 2018). All Washington sequences were annotated as either Marshallese or not Marshallese. To provide a “source” population for the extensive diversity among our disparate Washington introductions, we also specified a third, unsampled deme, for which migration was only allowed to proceed outward. As above, we inferred very few non-Marshallese internal nodes (**Supplemental Figures 6 and 7**). All internal nodes in the primary outbreak group are inferred as Marshallese with high probability, while non-Marshallese cases are present as terminal nodes. We recovered support for a single non-Marshallese cluster, indicating limited sustained transmission in the non-Marshallese population.

Structured coalescent models infer the effective population size (N_e) for each group, which reflects the number of infections necessary to generate the observed genetic diversity. Differences in N_e can result from different transmission rates or different numbers of infected individuals (Volz, 2012), and can therefore approximate differences in disease frequency between groups. While the total number of Marshallese and non-Marshallese cases reported through the public health surveillance system were similar (**Supplemental Table 2**), we

estimate that N_e for the non-Marshallese group is approximately 3 times higher than that of the Marshallese group. Assuming the same number of infected individuals in each group, lower N_e 's suggest higher transmission rates (Volz, 2012), suggesting more transmission within the Marshallese deme. Taken together, our results suggest that the outbreak was primarily sustained by transmission within the Marshallese community. While this transmission sometimes spilled over into the non-Marshallese community, transmission was generally not as successful there and died out, resulting in short, terminal transmission chains.

Viruses infecting vaccination groups individuals are genetically similar

Although only 9.7% of reported mumps cases in Washington were not up-to-date for mumps vaccination, infection of these individuals could have disproportionately impacted transmission in the state. Emergence of an antigenically novel strain of mumps could also allow infection of previously vaccinated individuals, and result in different virus lineages infecting individuals in different vaccination categories. We colored the tips of all Washington cases in our phylogeny to represent whether they were derived from individuals who were up-to-date, not up-to-date, or whose vaccination status was unknown. Mirroring overall vaccination coverage in Washington, the vast majority of samples in our dataset were from up-to-date individuals. The not up-to-date individuals present in our dataset are dispersed throughout the phylogeny and do not cluster together (**Fig. 6**), suggesting that there is no genetic difference between viruses infecting individuals with different vaccination statuses.

Figure 6: Individuals in different vaccination groups are infected by genetically similar viruses.

The exploded tree as shown in Figure 3a is shown, but tips are now colored by whether they represent cases from individuals who are up-to-date for mumps vaccination, not up-to-date, or cases for which vaccination status was unknown. The color of the large dot represents the inferred geographic location from which the Washington introduction was seeded.

Discussion

The resurgence of mumps in North America has ushered renewed attention towards understanding post-vaccine era mumps transmission. While many studies have used phylodynamic approaches to elucidate viral patterns of geographic spread (Dudas et al., 2017; Gouma et al., 2016; Grubaugh et al., 2017; Stapleton et al., 2019), using genomics to distinguish transmission patterns among epidemiologically distinct groups is novel. We employ a phylogenetic method (Vaughan et al., 2014) traditionally applied to geography that is robust to sampling bias (Dudas et al., 2018) to investigate drivers of mumps transmission in Washington. We show that the Washington State outbreak was fueled by approximately 13 independent introductions, primarily from Arkansas, leading to multiple co-circulating transmission chains.

Within Washington, transmission was more efficient within the Marshallese community. Marshallese individuals were more often sampled at the beginnings of transmission chains, contributed to longer transmission chains on average, and were overwhelmingly enriched on internal nodes within the phylogeny. We found no support for age or vaccination status as critical determinants of transmission in our outbreak, consistent with epidemiologic findings. Our data suggest that social networks can be critical determinants of mumps transmission. Future work exploring how social and economic disparities may amplify respiratory disease transmission will be necessary for updating outbreak mitigation and prevention strategies. By combining detailed metadata, novel metrics of transmission in the tree, and robust controls for sampling, we provide a framework for investigating source-sink dynamics that are readily applicable to other viral pathogens.

Our results highlight the utility of genomic data to clarify epidemiologic hypotheses. While genomic data and epidemiologic investigation (including case interviews and contact follow up) suggested an Arkansas introduction as the Washington outbreak's primary origin, sequence data revealed repeated and ongoing introductions into Washington, similar to patterns observed in Massachusetts, and the Netherlands (Gouma et al., 2016; Wohl et al., 2020). We also find widespread geographic mixing across the phylogeny, consistent with investigations from the US (Wohl et al., 2020), Canada (Stapleton et al., 2019), and Europe (Gavilán et al., 2018; Gouma et al., 2016). Like others (Gouma et al., 2016; Wohl et al., 2020), we confirm that SH genotyping alone is insufficient for fine-grained resolution of geographic transmission patterns. While CDC guidelines currently recommend SH-based genotyping specifically for tracking transmission pathways (Clemmons et al., 2020), building public health capacity for full-genome sequencing may provide better resolution for resolving local mumps transmission patterns.

Despite similar numbers of Marshallese and non-Marshallese cases, we find that mumps did not transmit efficiently among the general Washington populace. Washington State uses a passive surveillance system for mumps detection and case acquisition, which are known to frequently result in underreporting. Because the WA Department of Health did not perform active mump surveillance, it is difficult to assess whether different epidemiologic groups have different likelihoods of being sampled. Marshallese individuals are less likely to seek healthcare (Towne et al., 2020), which may have resulted in particularly high rates of underreporting in this group. Although statewide vaccine coverage is high, the risk for acquiring and transmitting mumps is clearly not equal across all Washington population groups. Provision of an outbreak dose of mumps-containing vaccine to high-risk groups may therefore be especially effective for limiting mumps transmission in future outbreaks. Others have reported success in using outbreak dose mumps vaccinations to reduce mumps transmission on college campuses (Cardemil et al., 2017; Shah et al., 2018) and in the US army (Arday et al., 1989; Eick et al., 2008; Green, 2006; Kelley et al., 1991), and the CDC currently recommends providing outbreak vaccine doses to individuals with increased risk due to an outbreak (Marlow et al., 2020). Future work to quantify the interplay between contact rates and vaccine-induced immunity among different age and risk groups should be used to guide updated vaccine recommendations.

Recent research has focused on identifying groups at risk for mumps infection due to their age (Lewnard and Grad, 2018), with less attention to other factors that may make populations vulnerable. In the 2016/017 Washington State outbreak, Marshallese status was a crucial predictor of transmission risk. Mumps has historically caused outbreaks in communities with strong, interconnected contact patterns (Barskey et al., 2012; Fields et al., 2019; Nelson et al., 2013), and in dense housing environments (Snijders et al., 2012). While a combination of waning immunity and dense housing settings make college campuses ideal for mumps

outbreaks, the Washington and Arkansas outbreaks show that populations other than young adults are at risk. Soliciting feedback from a Marshallese community health advocate allowed us to contextualize our genomic results with the lived experience of individuals most heavily affected during the outbreak and to identify reasonable hypotheses to explain the efficient transmission we observe. Based on these interviews and previously published studies, we speculate that within the Marshallese community, a combination of factors likely led to a high force of infection.

Multigenerational living is common in the Marshallese community (Fields et al., 2019), and Marshallese households tend to be larger on average (average household size = 5.28 (Harris and Jones, 2005), average household size for entire US populace = 2.52 (US Census Bureau, n.d.)). Having more household contacts may have facilitated a greater number and higher intensity of interactions among individuals, allowing the force of infection to overcome pre-existing immunity. It is also possible that infection intensity within the Marshallese community was exacerbated by low rates of insurance coverage and poor access to healthcare (McElfish et al., 2017; Towne et al., 2020), hesitancy to seek medical care (Williams and Hampton, 2005), and health disparities stemming from US occupation, nuclear testing, and exclusion from healthcare services. As part of reparations for US nuclear testing, the US signed the Compact of Free Association Treaty (COFA)(Congress, 2003) with the Marshall Islands in 1989, permitting Marshallese residents to live and work in the US without visas. However, eligibility for Medicaid was revoked for COFA immigrants in 1996, and US-residing Marshallese remain economically disadvantaged and under-insured (McElfish, 2016; McElfish et al., 2017, 2015). The passage of the Affordable Care Act (ACA) has not ameliorated these issues. Interviews with US-residing Marshallese note confusion among ACA staff regarding the legal status of COFA recipients, leading to drawn out enrollment processes that often leave individuals uninsured, frustrated

(McElfish et al., 2016), and far less likely to access care (Towne et al., 2020). A study of healthcare-seeking behavior among patients with diabetes showed that while multiple factors contribute to forgone care in the US populace, 77% of surveyed Marshallese individuals reported recent forgone care and cited lack of insurance as the primary reason (Towne et al., 2020). Marshallese trust in US medical institutions was seriously undermined by the unconsented use of Marshallese individuals for experiments on health impacts of nuclear exposure, with effects lingering today (Barker, 2012). Banked historical samples confirm uptake of radioactive materials in Marshallese inhabitants of affected Islands (Simon et al., 2010), but there has been limited published data on long-term health impacts of nuclear exposure, and significant concern remains within the community (Bordner et al., 2016). Finally, when Marshallese individuals do access care, they report experiencing disdain from healthcare workers (Duke, 2017) and sub-optimal care (McElfish et al., 2016). Interviews with medical workers show that blame for poor Marshallese health outcomes is sometimes placed on host genetics or cultural practices (Duke, 2017), poor health literacy (McElfish et al., 2018), or choosing to delay care (McElfish et al., 2018), with less consideration given to how the economic and legal impacts of US occupation affect the health of Marshallese individuals. These factors compound, and Marshallese individuals report hesitation to seek medical care, even when sick (McElfish et al., 2016). Hesitancy to seek care could have contributed to mumps transmission if sick individuals were primarily cared for at home without knowledge of or the ability to implement community-isolation protocols.

Our findings highlight that social networks can be the primary risk factor for a respiratory virus outbreak, even when a vaccine is effective and widely used. This finding is especially pertinent as SARS-CoV2 continues to disproportionately impact populations who live and work in high-risk settings, including the Marshallese (Center et al., 2020; McElfish et al., 2021), and for whom

vaccine licensure and distribution alone may not be a panacea. The passing of federal legislation remedying the exclusion of Marshallese individuals from Medicaid access (Hirono, 2019) in December 2020 marks an important step toward improving healthcare access for US-residing Marshallese. Future work to evaluate whether this change improves Marshallese access to healthcare and mitigates increased disease risk will be crucial follow-up. Future work should also explore whether nuclear exposure has impacted Marshallese immune function and susceptibility to infectious disease. Our findings demonstrate the importance of expanding our understanding of populations at risk for mumps re-emergence, so that rapid and comprehensive outbreak response strategies can be implemented to mitigate negative health impacts for all affected communities. Finally, future work to disentangle the complex interplay between healthcare access, social and economic disparity, and respiratory virus risk will be essential for mitigating health impacts of mumps and other respiratory viruses.

Materials and Methods

Data and Code Availability

All code used to analyze data, input files for BEAST, and all code used to generate figures for this manuscript are publicly available at <https://github.com/blab/mumps-wa-phylogenomics>. Raw FASTQ files with human reads removed are available under SRA project number PRJNA641715. All protocols for generating sequence data as well as the consensus genomes are available at <https://github.com/blab/mumps-seq>. Consensus genomes have also been deposited to Genbank under accessions MT859507-MT859672.

Community feedback

In order to ensure that this study was faithful to the experience of the Marshallese community in Washington State, we sought paid consultation from a local Marshallese community health advocate. We conducted video and telephone interviews to directly address the impacts of mumps transmission on the Marshallese community, community healthcare goals and priorities, and the impacts of the mumps outbreak on stigmatization. This feedback informed what is being presented herein, provided crucial context for understanding mumps transmission, and allowed us to work with the community to determine how best to discuss Marshallese involvement in the outbreak.

Mumps surveillance in Washington State

Mumps is a notifiable condition in Washington State. Therefore, per the Washington Administrative Code (WAC), as specified in WAC Chapter 246-101 (Washington State Legislature, 2014), healthcare providers, healthcare facilities, and laboratories must report cases of mumps or possible mumps to the local health jurisdiction (LHJ) of the patient's residence. LHJ staff initiate case investigations and facilitate optimal collection and testing of diagnostic specimens. Buccal swabs and urine are acceptable specimens for real-time reverse transcription polymerase chain reaction (qRT-PCR), a preferred diagnostic test for mumps. Most mumps rRT-PCR tests for Washington State residents are performed at the Washington State Public Health Laboratories, where all positive specimens are archived.

Individuals testing positive for mumps ribonucleic acid (RNA) by qRT-PCR are classified as confirmed mumps cases if they have a clinically-compatible illness (i.e., an illness involving parotitis or other salivary gland swelling lasting at least 2 days, aseptic meningitis, encephalitis, hearing loss, orchitis, oophoritis, mastitis, or pancreatitis). During case investigations, case-

patients or their proxies are interviewed. Information about demographics, illness characteristics, vaccination history, and potential for exposure to and transmission of mumps are solicited from each case-patient. In concordance with CDC guidelines (Centers for Disease Control and Prevention, 2019b), only vaccine doses for which there was written documentation with the date of vaccine receipt were considered valid. Individuals for which such documentation could not be provided were classified as having an unknown vaccination status. For individuals with documented vaccine doses, they were further characterized as up-to-date or not up-to-date based on their age. The Washington State Department of Health (DOH) receives, organizes, performs quality control on, and analyzes data from, LHJ case reports and supports investigations upon request.

Sample collection and IRB approval

This study was approved by the Fred Hutchinson Cancer Research Center (FHCRC) Institutional Review Board (IR File #: 6007-944) and by the Washington State Institutional Review Board, and classified as not involving human subjects. Samples were selected for sequencing to maximize temporal and epidemiologic breadth and to ensure successful sequencing. As such, samples were chosen based on the date of sample collection, the PCR cycle threshold (Ct), case vaccination status, and community status (Marshallese or non-Marshallese). Samples were selected for sequencing in 2 batches. In the first, samples were selected based on covering a wide geographic range within Washington, a full range of dates covering the outbreak, and having a Ct value < 36. This initial sampling regime resulted in a sample set skewed slightly towards samples from Marshallese individuals. To ensure that the proportion of samples in our data closely matched the distribution of cases in the outbreak, we then selected a second batch of samples using the same criteria as above, but excluded samples from Marshallese individuals. We then randomly sampled an additional 30 samples

from non-Marshallese individuals. This sampling regime resulted in a dataset that closely mirrors the distribution of metadata categories in the outbreak overall. All metadata, including case vaccination status, were transferred from WA DOH to FHCRC in a de-identified form.

We also sequenced an additional set of 56 samples collected in Wisconsin, Ohio, Missouri, Alabama, and North Carolina provided by the Wisconsin State Laboratory of Hygiene. 10 of these samples were collected in Wisconsin during the 2006/2007 Midwestern college campus outbreaks, 6 samples were collected in 2014, and the rest were collected between 2016 and 2018. For these samples, we received metadata describing sample Ct value and date of collection. All metadata were received by FHCRC in de-identified form.

Viral RNA extraction, cDNA synthesis, and amplicon generation

Viral RNA was extracted from buccal swabs using either the QiAmp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA) or the Roche MagNA Pure 96 DNA and viral NA small volume kit (Roche, Basel, Switzerland). For samples extracted with the QiAmp Viral RNA Mini Kit, 500 µl of buccal swab fluid was spun at 5000 x g for 5 minutes at 4°C to pellet host cells. The supernatant was then removed and centrifuged at 14,000 rpm for 90 minutes at 4°C to pellet virions. Excess fluid was discarded, and the pelleted virions were resuspended in 150-200 µl of fluid. Resuspended viral particles were then used as input to the QiAmp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA), following manufacturer's instructions, and eluting in 30 µl of buffer AVE. For extraction with the MagNA Pure, we followed manufacturer's instructions.

cDNA was generated with the Protoscript II First strand synthesis kit (New England Biolabs, Ipswich MD, USA), using 8 µl of vRNA as input and priming with 2 µl of random hexamers. vRNA and primers were incubated at 65°C for 5 minutes. Following this incubation, 10 µl of

Protoscript II reaction mix (2x) and 2 µl of Protoscript II enzyme mix (10x) were added to each reaction and incubated at 25°C for 5 minutes, then 42°C for 1 hour, followed by a final inactivation step at 80°C for 5 minutes. To amplify the full mumps genomes, we used Primal Scheme (<http://primal.zibraproject.org/>) to design overlapping, ~1500 base pair amplicons spanning the entirety of the mumps virus genome, where each tiled set of primes overlapped by ~100 base pairs. Primers are listed below.

Primer	Primer sequence	Forward/Reverse	Primer pool
mumps_1.5kb_1F	ACCAAGGGGAAAATGAAGATGGG	Forward	pool 1
mumps_1.5kb_1R	TAACGGCTGTGCTCTAAAGTCAT	Reverse	pool 1
mumps_1.5kb_2_F	TTGTTGACAGGCTTGCAAGAGG	Forward	pool 2
mumps_1.5kb_2_R	TTGTTCAAGATGTTGCAGGCGA	Reverse	pool 2
mumps_1.5kb_3_F	TGCAACCCCATATGCTCACCTA	Forward	pool 1
mumps_1.5kb_3_R	AGTTTGTTCTGCCTTTGCACA	Reverse	pool 1
mumps_1.5kb_4_F	AGTGAGAGCAGTTCAGATGGAAGT	Forward	pool 2
mumps_1.5kb_4_R	CCCTCCATTAGACCGGCACTTA	Reverse	pool 2
mumps_1.5kb_5_F	AACAACAGTGTTCAGCCACAA	Forward	pool 1
mumps_1.5kb_5_R	GGTGGCACTGTCCGATATTGTG	Reverse	pool 1
mumps_1.5kb_6_F	TGCCGTTCAATCATGAGACATAAAGA	Forward	pool 2
mumps_1.5kb_6_R	CGTAGAGGAGTTCATACGGCCA	Reverse	pool 2

mumps_1.5kb_7_F	TGTCTGTGCCTGGAATCAGATCT	Forward	pool 1
mumps_1.5kb_7_R	CGTCCTTCCAACATATCAGTGACC	Reverse	pool 1
mumps_1.5kb_8_F	CCAAAAGACAGGTGAGTTAACAGAT TT	Forward	pool 2
mumps_1.5kb_8_R	ACGAGCAAAGGGGATGATGACT	Reverse	pool 2
mumps_1.5kb_9_F	TTTGGCACACTCCGGTTCAAAT	Forward	pool 1
mumps_1.5kb_9_R	TGACAATGGTCTCACCTCCAGT	Reverse	pool 1
mumps_1.5kb_10_F	ACTCGCACAGTATCTATTAGATCGTG A	Forward	pool 2
mumps_1.5kb_10_R	GCCCAGCCAGAGTAAACAAACA	Reverse	pool 2
mumps_1.5kb_11_F	GCCAAGCAGATGGTAAACAGCA	Forward	pool 1
mumps_1.5kb_11_R	GGCTCTCTCCAACATGCTGTTC	Reverse	pool 1
mumps_1.5kb_12_F	GCGGGGCCTCTATGTCACTTAT	Forward	pool 2
mumps_1.5kb_12_R	CCAAGGGGAGAAAGTAAAATCAAT	Reverse	pool 2

568

569

570 Primers were pooled into 2 pools as follows: the first contained primer pairs 1, 3, 5, 7, 9, and 11,

571 all pooled at 10 uM. The second pool contained primer pairs 2, 4, 6, 8, 10, and 12. All primers in

572 pool 2 were pooled at 10 uM, except for primer pair 4, which was added at a 20 uM

573 concentration.

574

PCR was performed with the Q5 Hotstart DNA polymerase (New England Biolabs, Ipswich, MD, USA), using 11.75 μ l of nuclease-free water, 5 μ l of Q5 reaction buffer, 0.5 μ l of 10 mM dNTPs, 0.25 μ l, 2.5 of pooled primers, and 5 μ l of cDNA. Amplicons were generated with the following PCR cycling conditions: 98°C for 30 seconds, followed by 30 cycles of: 98°C for 15 seconds, then 67°C for 5 minutes. Cycling was concluded with a 10°C hold. PCR products were run on a 1% agarose gel, and bands were cut out and purified using the QiAquick gel extraction kit (Qiagen, Valencia, CA, USA), following the manufacturer's protocol. All optional steps were performed, and the final product was eluted in 30 μ l of buffer EB. For samples extracted on the MagNA Pure, amplicons were cleaned using a 1x bead cleanup with Ampure XP beads. Final cleaned amplicons were quantified using the Qubit dsDNA HS Assay kit (Thermo Fisher, Waltham, MA, USA).

Library preparation and sequencing

For each sample, pool 1 and pool 2 amplicons were combined in equimolar concentrations to a total of 0.5 ng in 2.5 μ l. Libraries were prepared using the Nextera XT DNA Library Prep Kit (Illumina, San Diego, CA, USA), following manufacturer's instructions, but with reagent volumes halved for each step, for the majority of samples in our dataset. For samples processed in our last sequencing run, several samples had higher Ct values. We therefore chose to process these samples using the standard 1x reagent volumes for the library preparation step. All libraries were purified using Ampure XP beads (Beckman Coulter, Brea, CA, USA), using a 0.6x cleanup, a 1x cleanup, and a final 0.7x cleanup. At each step, beads were washed twice with 200-400 μ l of 70% ethanol. The final product was eluted off the beads with 10 μ l of buffer EB. Tagmentation products were quantified with the Qubit dsDNA HS Assay kit (Thermo Fisher, Waltham, MA, USA), and run on a TapeStation with the TapeStation HighSense D5K assay (Agilent, Santa Clara, CA, USA) to determine the average fragment length. All but 8 samples

and negatives were pooled together in 6 nM libraries and run on 300 bp x 300 bp v3 kits on the Illumina MiSeq, with a 1% spike-in of PhiX. The remaining 8 samples (MuVs/Washington.USA/1.17/FH77[G], MuVs/Washington.USA/12.17/FH78[G], MuVs/Washington.USA/16.17/FH79[G], MuVs/Washington.USA/19.17/FH80[G], MuVs/Washington.USA/20.17/FH81[G], MuVs/Washington.USA/20.17/FH82[G], MuVs/Washington.USA/29.17/FH83[G], and MuVs/Washington.USA/2.17/FH84[G]) were pooled to a 1.2 nM library, and run as a 50 pM library with 2% PhiX on the Illumina iSeq, with a 151 bp x 151 bp v3 kit.

Negative controls

A negative control (nuclease-free water) was run for each viral RNA extraction, reverse transcription reaction, and for each pool for each PCR reaction. These negative controls were carried through the library preparation process and sequenced alongside actual samples. Any samples whose negative controls from any step in the process resulted in >10x mumps genome coverage were re-extracted and sequenced.

Bioinformatic processing of sequencing reads

Human reads were removed from raw FASTQ files by mapping to the human reference genome GRCH38 with bowtie2 (Langmead and Salzberg, 2012) version 2.3.2 (<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>). Reads that did not map to the human genome were output to separate FASTQ files and used for all subsequent analyses. Illumina data was analyzed using the pipeline described in detail at https://github.com/lmoncla/illumina_pipeline. Briefly, raw FASTQ files were trimmed using Trimmomatic (Bolger et al., 2014) (<http://www.usadellab.org/cms/?page=trimmomatic>), trimming in sliding windows of 5 base pairs and requiring a minimum Q-score of 30. Reads that were trimmed to a length of <100 base pairs were discarded. Trimming was performed with the following command: java -jar

Trimmomatic-0.36/trimmomatic-0.36.jar SE input.fastq output.fastq SLIDINGWINDOW:5:30
 MINLEN:100. Trimmed reads were mapped to a consensus sequence from Massachusetts
 (Genbank accession: MF965301) using bowtie2(Langmead and Salzberg, 2012) version 2.3.2
 (<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>), using the following command: bowtie2 -
 x reference_sequence.fasta -U read1.trimmed.fastq,read2.trimmed.fastq -S output.sam --local.
 We selected this Massachusetts sequence as an initial reference sequence because at the
 time, it represented one of the only available genomes of a genotype G mumps virus that had
 been sampled during a US outbreak in 2016. Mapped reads were imported into Geneious
 (<https://www.geneious.com/>) for visual inspection and consensus calling. To avoid issues with
 mapping to an improper reference sequence, we then remapped each sample's trimmed
 FASTQ files to its own consensus sequence. These bam files were again manually inspected in
 Geneious, and a final consensus sequence was called, with nucleotide sites with <20x coverage
 output as an ambiguous nucleotide ("N"). All genomes with >50% Ns were discarded. In total,
 we generated 140 genomes with at least 80% non-N bases, and 26 genomes with 50-80% non-
 N bases. Our median completeness (percent of bases that are not Ns) across the dataset is
 90%. All genomes used in these analyses are available at [https://github.com/blab/mumps-](https://github.com/blab/mumps-seq/tree/master/data)
[seq/tree/master/data](https://github.com/blab/mumps-seq/tree/master/data).

Dataset curation and maximum likelihood divergence tree generation

We downloaded all currently available (as of June 2020), complete mumps genomes from North
 America from the NIAID Virus Pathogen Database and Analysis Resource (ViPR) (Pickett et al.,
 2012) through <http://www.viprbrc.org/>. We also obtained mumps genomes from British
 Columbia, Ontario, and Arkansas. We obtained written permission from sequence authors for
 any sequence that had not previously been published on. In total, this dataset includes 437 full
 mumps genomes from North America. Sequences and metadata were cleaned and organized

using fauna, a database system that is part of the Nextstrain platform. Sequences were processed using Nextstrain's augur software (Hadfield et al., 2018), and filtered to include only those with at least 8,000 bases and were sampled in North America in 2006 or later. Genomes were aligned with MAFFT (Kato et al., 2002), and trimmed to the reference sequence (MuV/Gabon/13/2[G], GenBank accession: KM597072). We inferred a maximum likelihood phylogeny using IQTREE (Nguyen et al., 2015) with a GTR nucleotide substitution model, and inferred a molecular clock and temporally-resolved phylogeny using TreeTime (Saguenko et al., 2018). Sequences with an estimated clock rate that deviated from the other sequences by >4 times the interquartile distance were removed from subsequent analysis. We inferred the root-to-tip distance with TempEst version 1.5.1 (Rambaut et al., 2016) with the best fitting root by the heuristic residual mean squared function.

Phylogenetic analysis of full North American mumps genomes

Using the same set of genome sequences used for divergence tree estimation, we aligned sequences with MAFFT and inferred time-resolved phylogenies in BEAST version 1.8.4 (Drummond et al., 2012). We used a skygrid population size prior with 100 bins, and a skygrid cutoff of 25 years, allowing us to estimate 4 population sizes each year. We used an HKY nucleotide substitution model with 4 gamma rate categories, and a strict clock with a CTMC prior. We used a discrete trait model (Lemey et al., 2009) and estimated migration rates using BSSVS and ancestral states with 27 geographic locations. Here, "state" refers to the inferred ancestral identity of an internal node, where the inferred identity could be any of the 27 geographic locations (US states and Canadian provinces) in the dataset. For the prior on non-zero rates for BSSVS, we specified an exponential distribution with a mean of 26. As a prior on each pairwise migration rate, we used an exponential distribution with mean 1. All other priors were left at default values. We ran this analysis for 100 million steps, sampling every 10,000,

and removed the first 10% of sampled states as burnin. A maximum clade credibility tree was summarized with TreeAnnotator, using the mean heights option. All tree plotting was performed with baltic (<https://github.com/evogytis/baltic>). Input XML files and output results are available at <https://github.com/blab/mumps-wa-phylogenetics/tree/master/phylogeography>.

Testing for descendants in divergence trees

To determine whether specific groups were more likely to be found at the beginnings of transmission chains than other groups, we developed a statistic to quantify transmission in the tree. Using the tree JSON output from the Nextstrain pipeline (Hadfield et al., 2018), we traversed the tree from root to tip. For each tip that lay on an internal node, i.e., had a branch length of nearly 0 ($< 1 \times 10^{-16}$), we counted the number of descendants. We collapsed very small branches (those with branch lengths less 1×10^{-16}) to obtain polytomies. We then classified tips as either having descendants (i.e., the number of descendants was > 0) or not having descendants. Here, we define a “descendant” as a tip that occurs in any downstream portion of the tree, i.e., it falls along the same lineage but to the right of the parent tip. A diagram of what we classify as “descendant tips” is shown in Figure 4a. The probability of having descendants was evaluated as a function of community status, age, and vaccination status with logistic regression as described below.

For each Washington tip in the tree, we classified it as either having descendants (coded as a 1) or not having descendants (coded as 0). For each tip, we coded its corresponding age, vaccination status, and community membership as a predictor variable input into a logistic regression model. We coded these attributes as follows: For community membership, non-Marshallese tips were coded as 0 and Marshallese tips were coded as 1. Age was coded as a single, continuous variable. In our dataset, there were 3 classifications for vaccination status:

up-to-date, not up-to-date, and unknown vaccination status. According to the Advisory Committee on Immunization Practices (ACIP) (McLean et al., 2013), individuals aged 5-18 had to have received both recommended doses of mumps-containing vaccine, children aged 15 months to 5 years required 1 dose of mumps-containing vaccine, and adults over 18 had to have received at least 1 dose of mumps-containing vaccine to be classified as up-to-date for mumps vaccination. Individuals under 15 months are considered up-to-date without any doses of mumps-containing vaccine. Not up-to-date individuals are those with a known vaccination status who did not qualify under criteria to be classified as up-to-date. Individuals who could not provide documentation regarding their MMR vaccination history were considered to have “unknown” vaccination status. Individuals with “known” vaccination status could either be fully up-to-date, undervaccinated, or unvaccinated. To ensure that we measured the effect of vaccination among individuals who knew their vaccination status, we coded vaccination information using two dummy variables in our logistic regression, one signifying whether vaccination status was known or not, and one indicating whether vaccination was up-to-date or not. We then fit a logistic regression model to this data using the glm package in R (<https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/glm>), specifying a binomial model as

$$\text{Pr}(\text{having descendants}) \sim \beta_0 + \beta_1 x_1 + \beta_2 x_2 + \beta_3 x_3 + \beta_4 x_4,$$

where x_1 represents 0 or 1 value for member of Marshallese community (Not Marshallese coded as a 0, Marshallese coded as a 1), x_2 represents the numeric value of age, x_3 represents 0 or 1 value for whether vaccination status is unknown (having a known vaccination status coded as a 0, having an unknown vaccination status coded as a 1) and x_4 represents 0 or 1 value for whether vaccination status is up-to-date (up-to-date coded as a 0 and not up-to-date coded as a 1). Under this formulation, an individual with unknown vaccination status would be coded as $x_3=1$, $x_4=0$, an individual who is up-to-date

would be coded as $x_3=0$, $x_4=0$, and an individual who is not up-to-date is coded as $x_3=0$, $x_4=1$.

This encoding allows us to evaluate the effects of having an unknown vaccination status and a vaccination status that is not up-to-date. Age was normalized such that values fall between 0 and 1 by: $(x_2 - \text{minimum age in dataset}) / (\text{maximum age in dataset} - \text{minimum age in dataset})$.

P-values were assigned via a Wald test, and inferred coefficients were exponentiated to return odds ratios. All code used to parse the divergence tree and formulate and fit the regression model are available at <https://github.com/blab/mumps-wa-phylogenetics/blob/master/divergence-tree-analyses/Regression-analysis-on-descendants-in-divergence-tree.ipynb>.

Rarefaction analysis to estimate transmission clusters

Using the full set of North American mumps sequences, we designated all non-Washington North American sequences as “background” sequences. We then separated Washington sequences into Marshallese tips (57 total sequences) and non-Marshallese tips (52 total sequences). For this analysis, we excluded the genotype K sequence in our dataset due to its extreme divergence from other viruses sampled in Washington, which were all genotype G. For each group (Marshallese vs. non-Marshallese), we then generated subsampled datasets comprised of a random sample of 1 to n sequences, where n is the number of total sequences available for that group. For each number of sequences, we performed 10 independent subsampling trials. Subsampling was performed without replacement. So, for community members, we generated 10 datasets in which 1 community member sequence was sampled, then 10 datasets in which 2 community members sequences were sampled, etc. up to 10 datasets in which all 57 community members sequences were sampled. For each subsampled dataset, we then combined these subsampled datasets with the background North American

sequences, and reran the Nextstrain pipeline. For each subsample and trial, we infer geographic transmission history across the tree and enumerate the number of introductions into Washington. Geographic transmission history was inferred using a discrete trait model in TreeTime(Sagulenko et al., 2018). For each number of sequences tested, n , we report the number of trials resulting in that number of inferred introductions, and the mean number of inferred introductions across the 10 trials. Each resulting “cluster” consisted of a set of sequences that are related to one another that descend from a single inferred introduction of mumps into Washington.

Inference of community transmission dynamics using a structured coalescent model

To infer the rates of migration between community and non-community members and to infer ancestral states of Washington internal nodes, we employed a structured coalescent model. Here, “state” refers to the inferred ancestral identity of an internal node, where the identity could be inferred as “Marshallese” or “not Marshallese”. The multitype tree model (Vaughan et al., 2014) in BEAST 2 v2.6.2 (Bouckaert et al., 2019) infers the effective population sizes of each deme and the migration rates between them. Because the multitype tree model requires that all partitions contain all demes, we could only analyze 4 clades that circulated in Washington State and included both Marshallese and non-Marshallese tips. We generated an XML in BEAUti v2.6.2 with 4 partitions, and linked the clock, site, and migration models. We used a strict, fixed clock, set to 4.17×10^{-4} substitutions per site year, and used an HKY substitution model with 4 gamma-distributed rate categories. This clock rate was set based on the inferred substitutions per site per year from all North American mumps genomes on nextstrain.org/mumps/na. Migration rates were inferred with the prior specified as a truncated exponential distribution with a mean of 1 and a maximum of 50. Effective population sizes were inferred with the prior specified as a truncated exponential distribution with a mean of 1, a minimum value of 0.001,

and a maximum value of 10,000. All other priors were left at default values. In order to improve convergence, we employed 3 heated chains using the package CoupledMCMC (Müller and Bouckaert, 2019), where proposals for chains to swap were performed every 100 states. The analysis was run for 100 million steps, with states sampled every 1 million steps. We ran this analysis 3 independent times, and combined log and tree file output from those independent runs using LogCombiner, with the first 10% (1000 states) of each run discarded as burnin. We then summarized these combined output log and tree files. A maximum clade credibility tree was inferred using TreeAnnotator with the mean heights option. To ensure that results were not appreciably altered by the migration rate prior, we also repeated these analyses with migration rates inferred with the prior specified as a truncated exponential distribution with a mean of 10 and a maximum of 50.

Although our complete dataset contains approximately equal numbers of sequences from Marshallese and non-Marshallese cases, the 4 clusters analyzed above are enriched among Marshallese tips. To assess the impact of uneven sampling within these clusters on ancestral state inference, we performed a subsampling analysis. For each cluster, we subsampled down the number of Marshallese tips to be equal to the number of non-Marshallese tips, and reran the analysis as above. While the original analysis used 4 subclades containing both Marshallese and non-Marshallese tips, one of these subclades only has 5 tips. Subsampling this particular subtree would have resulted in a subtree with only 2 tips, thus we excluded this clade from the subsampling analysis. For this sensitivity analysis, the 3 subsampled datasets had the following tip composition: primary outbreak clade: 26 Marshallese and 26 non-Marshallese tips; 10-tip introduction: 3 Marshallese and 3 non-Marshallese tips; 8-tip introduction: 4 Marshallese and 4 non-Marshallese tips. We generated 3 randomly subsampled datasets, and for each one ran 3 independent chains, with each chain run for 50 million steps, sampling every 500,000. For one

of the subsampled datasets, none of the chains converged after 20 days. In each of the remaining 2 subsampled datasets, 2 out of 3 chains converged. We combined these converged chains using LogCombiner, with the first 10% of each run discarded as burn-in. We then summarized these combined output log and tree files, and inferred a maximum clade credibility tree using TreeAnnotator with the mean heights option.

The analysis as described above assumes that each introduction into Washington State is an independent observation of the same structured coalescent process, and that the dataset represents a random sample of the underlying population. Additionally, this approach requires a *priori* definition of which sequences are part of the same Washington State transmission chain. Finally, the above analysis could only make use of the 4 Washington introductions with both Marshallese and non-Marshallese tips, and excludes other transmission chains. Because of these issues, we supplemented the above approach with an additional analysis using the approximate structured coalescent (Müller et al., 2017) in MASCOT (Müller et al., 2018). Using all of the Washington sequences, we specified three demes: Marshallese in Washington, non-Marshallese in Washington, and outside of Washington. To account for any transmission that happened outside of Washington State, the “outside of Washington” deme acted as a “ghost deme” from which we did not use any samples. The effective population size of this “outside of Washington” deme then describes the rate at which lineages between any location outside of Washington share a common ancestor. Including specific samples from outside of Washington would bias the inferred effective population size towards the coalescent rates of the sampled locations, by incorporating local transmission dynamics of other locations. We then estimated migration rates and effective population sizes for all 3 demes, but fixed the migration rates such that the unsampled deme (“outside of Washington”) could only act as a source population. This is motivated by not having observed obvious migration out of Washington State in our previous

analysis here. We ran this analysis for 10 million steps, sampling every 5000, and discarded the first 10% of states as burnin.

References

- Abella MKIL, Molina MR, Nikolić-Hughes I, Hughes EW, Ruderman MA. 2019. Background gamma radiation and soil activity measurements in the northern Marshall Islands. *Proc Natl Acad Sci U S A* **116**:15425–15434. doi:10.1073/pnas.1903421116
- Adams WH, Fields HA, Engle JR, Hadler SC. 1986. Serologic markers for hepatitis B among Marshallese accidentally exposed to fallout radiation in 1954. *Radiat Res* **108**:74–79.
- Arday DR, Kanjarpane DD, Kelley PW. 1989. Mumps in the US Army 1980-86: should recruits be immunized? *Am J Public Health* **79**:471–474. doi:10.2105/ajph.79.4.471
- Barker HM. 2012. Bravo for the Marshallese: Regaining Control in a Post-Nuclear, Post-Colonial World. Cengage Learning.
- Barskey AE, Schulte C, Rosen JB, Handschur EF, Rausch-Phung E, Doll MK, Cummings KP, Alleyne EO, High P, Lawler J, Apostolou A, Blog D, Zimmerman CM, Montana B, Harpaz R, Hickman CJ, Rota PA, Rota JS, Bellini WJ, Gallagher KM. 2012. Mumps outbreak in Orthodox Jewish communities in the United States. *N Engl J Med* **367**:1704–1713. doi:10.1056/NEJMoa1202865
- Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **30**:2114–2120. doi:10.1093/bioinformatics/btu170
- Bordner AS, Crosswell DA, Katz AO, Shah JT, Zhang CR, Nikolic-Hughes I, Hughes EW, Ruderman MA. 2016. Measurement of background gamma radiation in the northern Marshall Islands. *Proc Natl Acad Sci U S A* **113**:6833–6838. doi:10.1073/pnas.1605535113
- Bouckaert R, Vaughan TG, Barido-Sottani J, Duchêne S, Fourment M, Gavryushkina A, Heled

J, Jones G, Kühnert D, De Maio N, Matschiner M, Mendes FK, Müller NF, Ogilvie HA, du Plessis L, Poppinga A, Rambaut A, Rasmussen D, Siveroni I, Suchard MA, Wu C-H, Xie D, Zhang C, Stadler T, Drummond AJ. 2019. BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis. *PLoS Comput Biol* **15**:e1006650. doi:10.1371/journal.pcbi.1006650

Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, Marin M, Riley J, Feikin DR, Patel M, Quinlisk P. 2017. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. *N Engl J Med* **377**:947–956. doi:10.1056/NEJMoa1703309

CDCMMWR. 2019. Notifiable Diseases and Mortality Tables.

Center KE, Da Silva J, Hernandez AL, Vang K, Martin DW, Mazurek J, Lilo EA, Zimmerman NK, Krow-Lucal E, Campbell EM, Cowins JV, Walker C, Dominguez KL, Gallo B, Gunn JKL, McCormick D, Cochran C, Smith MR, Dillaha JA, James AE. 2020. Multidisciplinary Community-Based Investigation of a COVID-19 Outbreak Among Marshallese and Hispanic/Latino Communities - Benton and Washington Counties, Arkansas, March-June 2020. *MMWR Morb Mortal Wkly Rep* **69**:1807–1811. doi:10.15585/mmwr.mm6948a2

Centers for Disease Control and Prevention. 2019a. Health Departments: How to Optimize Mumps Testing | CDC. *Guidance for Optimizing Mumps Testing*. <https://www.cdc.gov/mumps/health-departments/optimize-testing.html>

Centers for Disease Control and Prevention. 2019b. Epidemiology and Prevention of Vaccine-Preventable Diseases, The Pink Book: Course Textbook. Centers for Disease Control and Prevention.

Clemmons N, Hickman C, Lee A, Mona Marin M, Patel M. 2020. Manual for the Surveillance of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention.

Congress 108th United States. 2003. Compact of Free Association Amendments Act of 2003.

Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. 2008. Persistence of measles, mumps,

and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. *J Infect Dis* **197**:950–956. doi:10.1086/528993

De Maio N, Wu CH, O'Reilly KM, Wilson D. 2015. New Routes to Phylogeography: A Bayesian Structured Coalescent Approximation. *PLoS Genet*. doi:10.1371/journal.pgen.1005421

Drummond AJ, Suchard MA, Xie D, Rambaut A. 2012. Bayesian phylogenetics with BEAUti and the BEAST 1.7. *Mol Biol Evol* **29**:1969–1973. doi:10.1093/molbev/mss075

Dudas G, Carvalho LM, Bedford T, Tatem AJ, Baele G, Faria NR, Park DJ, Ladner JT, Arias A, Asogun D, Bielejec F, Caddy SL, Cotten M, D'Ambrozio J, Dellicour S, Di Caro A, Diclaro JW, Duraffour S, Elmore MJ, Fakoli LS, Faye O, Gilbert ML, Gevao SM, Gire S, Gladden-Young A, Gnirke A, Goba A, Grant DS, Haagmans BL, Hiscox JA, Jah U, Kugelman JR, Liu D, Lu J, Malboeuf CM, Mate S, Matthews DA, Matranga CB, Meredith LW, Qu J, Quick J, Pas SD, Phan MVT, Pollakis G, Reusken CB, Sanchez-Lockhart M, Schaffner SF, Schieffelin JS, Sealfon RS, Simon-Loriere E, Smits SL, Stoecker K, Thorne L, Tobin EA, Vandi MA, Watson SJ, West K, Whitmer S, Wiley MR, Winnicki SM, Wohl S, Wölfel R, Yozwiak NL, Andersen KG, Blyden SO, Bolay F, Carroll MW, Dahn B, Diallo B, Formenty P, Fraser C, Gao GF, Garry RF, Goodfellow I, Günther S, Happi CT, Holmes EC, Kargbo B, Keita S, Kellam P, Koopmans MPG, Kuhn JH, Loman NJ, Magassouba N 'faly, Naidoo D, Nichol ST, Nyenswah T, Palacios G, Pybus OG, Sabeti PC, Sall A, Ströher U, Wurie I, Suchard MA, Lemey P, Rambaut A. 2017. Virus genomes reveal factors that spread and sustained the Ebola epidemic. *Nature* **544**:309–315. doi:10.1038/nature22040

Dudas G, Carvalho LM, Rambaut A, Bedford T. 2018. MERS-CoV spillover at the camel-human interface. *Elife*. doi:10.7554/eLife.31257

Duke MR. 2017. Neocolonialism and Health Care Access among Marshall Islanders in the United States. *Med Anthropol Q* **31**:422–439. doi:10.1111/maq.12376

Eick AA, Hu Z, Wang Z, Nevin RL. 2008. Incidence of mumps and immunity to measles, mumps

and rubella among US military recruits, 2000-2004. *Vaccine* **26**:494–501.

doi:10.1016/j.vaccine.2007.11.035

Fields VS, Safi H, Waters C, Dillaha J, Capelle L, Riklon S, Wheeler JG, Haselow DT. 2019.

Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak

report. *Lancet Infect Dis* **19**:185–192. doi:10.1016/S1473-3099(18)30607-8

Gavilán AM, Fernández-García A, Rueda A, Castellanos A, Masa-Calles J, López-Perea N,

Torres de Mier MV, de Ory F, Echevarría JE. 2018. Genomic non-coding regions reveal

hidden patterns of mumps virus circulation in Spain, 2005 to 2015. *Euro Surveill* **23**.

doi:10.2807/1560-7917.ES.2018.23.15.17-00349

Gouma S, Cremer J, Parkkali S, Veldhuijzen I, van Binnendijk RS, Koopmans MPG. 2016.

Mumps virus F gene and HN gene sequencing as a molecular tool to study mumps virus

transmission. *Infect Genet Evol* **45**:145–150. doi:10.1016/j.meegid.2016.08.033

Green CB. 2006. Updated Vaccine Guidance for Adults and Accessions-June 2006.

Grubaugh ND, Ladner JT, Kraemer MUG, Dudas G, Tan AL, Gangavarapu K, Wiley MR, White

S, Thézé J, Magnani DM, Prieto K, Reyes D, Bingham AM, Paul LM, Robles-Sikisaka R,

Oliveira G, Pronty D, Barcellona CM, Metsky HC, Baniecki ML, Barnes KG, Chak B, Freije

CA, Gladden-Young A, Gnirke A, Luo C, MacInnis B, Matranga CB, Park DJ, Qu J,

Schaffner SF, Tomkins-Tinch C, West KL, Winnicki SM, Wohl S, Yozwiak NL, Quick J,

Fauver JR, Khan K, Brent SE, Reiner RC Jr, Lichtenberger PN, Ricciardi MJ, Bailey VK,

Watkins DI, Cone MR, Kopp EW 4th, Hogan KN, Cannons AC, Jean R, Monaghan AJ,

Garry RF, Loman NJ, Faria NR, Porcelli MC, Vasquez C, Nagle ER, Cummings DAT,

Stanek D, Rambaut A, Sanchez-Lockhart M, Sabeti PC, Gillis LD, Michael SF, Bedford T,

Pybus OG, Isern S, Palacios G, Andersen KG. 2017. Genomic epidemiology reveals

multiple introductions of Zika virus into the United States. *Nature* **546**:401–405.

doi:10.1038/nature22400

923 Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,
 924 Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*
 925 **34**:4121–4123. doi:10.1093/bioinformatics/bty407

926 Hallgren EA, McElfish PA, Rubon-Chutaro J. 2015. Barriers and opportunities: a community-
 927 based participatory research study of health beliefs related to diabetes in a US Marshallese
 928 community. *Diabetes Educ* **41**:86–94. doi:10.1177/0145721714559131

929 Harris PM, Jones NA. 2005. We the People: Pacific Islanders in the United States. US
 930 Department of Commerce.

931 Hirono MK. 2019. Covering our FAS Allies Act.

932 Katoh K, Misawa K, Kuma KK-I, Miyata T. 2002. MAFFT: a novel method for rapid multiple
 933 sequence alignment based on fast Fourier transform. *Nucleic Acids Res* **30**:3059–3066.
 934 doi:10.1093/nar/gkf436

935 Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. 1991. The susceptibility of
 936 young adult Americans to vaccine-preventable infections. A national serosurvey of US
 937 Army recruits. *JAMA* **266**:2724–2729. doi:10.1001/jama.1991.03470190072032

938 Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
 939 **9**:357–359. doi:10.1038/nmeth.1923

940 Lemey P, Rambaut A, Drummond AJ, Suchard MA. 2009. Bayesian phylogeography finds its
 941 roots. *PLoS Comput Biol*. doi:10.1371/journal.pcbi.1000520

942 Lewnard JA, Grad YH. 2018. Vaccine waning and mumps re-emergence in the United States.
 943 *Sci Transl Med* **10**. doi:10.1126/scitranslmed.aao5945

944 Marlow MA, Marin M, Moore K, Patel M. 2020. CDC Guidance for Use of a Third Dose of MMR
 945 Vaccine During Mumps Outbreaks. *J Public Health Manag Pract* **26**:109–115.
 946 doi:10.1097/PHH.0000000000000962

947 McElfish PA. 2016. Marshallese COFA Migrants in Arkansas. *J Ark Med Soc* **112**:259–60, 262.

McElfish PA, Chughtai A, Low LK, Garner R, Purvis RS. 2018. “Just doing the best we can”: health care providers’ perceptions of barriers to providing care to Marshallese patients in Arkansas. *Ethn Health* 1–14. doi:10.1080/13557858.2018.1471670

McElfish PA, Hallgren E, Yamada S. 2015. Effect of US health policies on health care access for Marshallese migrants. *Am J Public Health* **105**:637–643. doi:10.2105/AJPH.2014.302452

McElfish PA, Purvis RS, Maskarinec GG, Bing WI, Jacob CJ, Ritok-Lakien M, Rubon-Chutaro J, Lang S, Mamis S, Riklon S. 2016. Interpretive policy analysis: Marshallese COFA migrants and the Affordable Care Act. *Int J Equity Health* **15**:91. doi:10.1186/s12939-016-0381-1

McElfish PA, Purvis R, Willis DE, Riklon S. 2021. COVID-19 Disparities Among Marshallese Pacific Islanders. *Prev Chronic Dis* **18**:E02. doi:10.5888/pcd18.200407

McElfish PA, Rowland B, Long CR, Hudson J, Piel M, Buron B, Riklon S, Bing WI, Warmack TS. 2017. Diabetes and Hypertension in Marshallese Adults: Results from Faith-Based Health Screenings. *J Racial Ethn Health Disparities* **4**:1042–1050. doi:10.1007/s40615-016-0308-y

McLean HQ, Amy Parker Fiebelkorn MSN, Temte JL, Wallace GS. 2013. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013. <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm>

Müller NF, Bouckaert R. 2019. Coupled MCMC in BEAST 2. *bioRxiv*. doi:10.1101/603514

Müller NF, Rasmussen DA, Stadler T. 2017. The Structured Coalescent and Its Approximations. *Molecular Biology and Evolution*. doi:10.1093/molbev/msx186

Müller NF, Rasmussen D, Stadler T. 2018. MASCOT: parameter and state inference under the marginal structured coalescent approximation. *Bioinformatics*. doi:10.1093/bioinformatics/bty406

Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, Lizama A, Diras D, Mathew A, Camacho EJ, Monforte M-N, Chen T-H, Mahamud A, Kutty PK, Hickman C, Bellini WJ,

Seward JF, Gallagher K, Fiebelkorn AP. 2013. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010. *Pediatr Infect Dis J* **32**:374–380. doi:10.1097/INF.0b013e318279f593

Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. 2015. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* **32**:268–274. doi:10.1093/molbev/msu300

Niedenthal J. 1997. A history of the people of Bikini following nuclear weapons testing in the Marshall Islands: with recollections and views of elders of Bikini Atoll. *Health Phys* **73**:28–36. doi:10.1097/00004032-199707000-00003

Palafox NA, Riklon S, Alik W, Hixon AL. 2007. Health consequences and health systems response to the Pacific U.S. Nuclear Weapons Testing Program. *Pac Health Dialog* **14**:170–178.

Pickett BE, Sadat EL, Zhang Y, Noronha JM, Squires RB, Hunt V, Liu M, Kumar S, Zaremba S, Gu Z, Zhou L, Larson CN, Dietrich J, Klem EB, Scheuermann RH. 2012. ViPR: an open bioinformatics database and analysis resource for virology research. *Nucleic Acids Res* **40**:D593–8. doi:10.1093/nar/gkr859

Rambaut A, Lam TT, Max Carvalho L, Pybus OG. 2016. Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol* **2**:vew007. doi:10.1093/ve/vew007

Sagulenko P, Puller V, Neher RA. 2018. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus Evolution* **4**. doi:10.1093/ve/vex042

Shah M, Quinlisk P, Weigel A, Riley J, James L, Patterson J, Hickman C, Rota PA, Stewart R, Clemmons N, Kalas N, Cardemil C, Iowa Mumps Outbreak Response Team. 2018. Mumps Outbreak in a Highly Vaccinated University-Affiliated Setting Before and After a Measles-

998 Mumps-Rubella Vaccination Campaign-Iowa, July 2015-May 2016. *Clin Infect Dis* **66**:81–
999 88. doi:10.1093/cid/cix718

1000 Simon SL. 1997. A brief history of people and events related to atomic weapons testing in the
1001 Marshall Islands. *Health Phys* **73**:5–20. doi:10.1097/00004032-199707000-00001

1002 Simon SL, Bouville A, Melo D, Beck HL, Weinstock RM. 2010. Acute and chronic intakes of
1003 fallout radionuclides by Marshallese from nuclear weapons testing at Bikini and Enewetak
1004 and related internal radiation doses. *Health Phys* **99**:157–200.
1005 doi:10.1097/HP.0b013e3181dc4e51

1006 Snijders BEP, van Lier A, van de Kasstelee J, Fanoy EB, Ruijs WLM, Hulshof F, Blauwhof A,
1007 Schipper M, van Binnendijk R, Boot HJ, de Melker HE, Hahné SJM. 2012. Mumps vaccine
1008 effectiveness in primary schools and households, the Netherlands, 2008. *Vaccine* **30**:2999–
1009 3002. doi:10.1016/j.vaccine.2012.02.035

1010 Stapleton PJ, Eshaghi A, Seo CY, Wilson S, Harris T, Deeks SL, Bolotin S, Goneau LW,
1011 Gubbay JB, Patel SN. 2019. Evaluating the use of whole genome sequencing for the
1012 investigation of a large mumps outbreak in Ontario, Canada. *Sci Rep* **9**:12615.
1013 doi:10.1038/s41598-019-47740-1

1014 Takahashi T, Trott KR, Fujimori K, Simon SL, Ohtomo H, Nakashima N, Takaya K, Kimura N,
1015 Satomi S, Schoemaker MJ. 1997. An investigation into the prevalence of thyroid disease on
1016 Kwajalein Atoll, Marshall Islands. *Health Phys* **73**:199–213. doi:10.1097/00004032-
1017 199707000-00017

1018 Towne SD, Yeary KHK, Narcisse M-R, Long C, Bursac Z, Totaram R, Rodriguez EM, McElfish
1019 P. 2020. Inequities in Access to Medical Care Among Adults Diagnosed with Diabetes:
1020 Comparisons Between the US Population and a Sample of US-Residing Marshallese
1021 Islanders. *J Racial Ethn Health Disparities*. doi:10.1007/s40615-020-00791-x

1022 US Census Bureau. n.d. Historical Households Tables.

- 1023 Vaughan TG, Kühnert D, Poppinga A, Welch D, Drummond AJ. 2014. Efficient Bayesian
- 1024 inference under the structured coalescent. *Bioinformatics*.
- 1025 doi:10.1093/bioinformatics/btu201
- 1026 Volz EM. 2012. Complex population dynamics and the coalescent under neutrality. *Genetics*
- 1027 **190**:187–201. doi:10.1534/genetics.111.134627
- 1028 Washington State Legislature. 2014. Chapter 246-101 WAC. *Chapter 246-101 WAC Notifiable*
- 1029 *Conditions*. <https://app.leg.wa.gov/wac/default.aspx?cite=246-101>
- 1030 Williams DP, Hampton A. 2005. Barriers to health services perceived by Marshallese
- 1031 immigrants. *J Immigr Health* **7**:317–326. doi:10.1007/s10903-005-5129-8
- 1032 Wohl S, Metsky HC, Schaffner SF, Piantadosi A, Burns M, Lewnard JA, Chak B, Krasilnikova
- 1033 LA, Siddle KJ, Matranga CB, Bankamp B, Hennigan S, Sabina B, Byrne EH, McNall RJ,
- 1034 Shah RR, Qu J, Park DJ, Gharib S, Fitzgerald S, Barreira P, Fleming S, Lett S, Rota PA,
- 1035 Madoff LC, Yozwiak NL, MacInnis BL, Smole S, Grad YH, Sabeti PC. 2020. Combining
- 1036 genomics and epidemiology to track mumps virus transmission in the United States. *PLoS*
- 1037 *Biol* **18**:e3000611. doi:10.1371/journal.pbio.3000611
- 1038 Wong DC, Purcell RH, Rosen L. 1979. Prevalence of antibody to hepatitis A and hepatitis B
- 1039 viruses in selected populations of the South Pacific. *Am J Epidemiol* **110**:227–236.
- 1040 doi:10.1093/oxfordjournals.aje.a112807
- 1041 Yamada S, Dodd A, Soe T, Chen T-H, Bauman K. 2004. Diabetes mellitus prevalence in out-
- 1042 patient Marshallese adults on Ebeye Island, Republic of the Marshall Islands. *Hawaii Med J*
- 1043 **63**:45–51.

1044

1045 Acknowledgments

We would like to extend our sincerest thank you to Jiji Jally for her help and input on the project. Jiji Jally is an advocate for affordable access to healthcare services, supportive services for the Marshallese community, and works as a translator to assist the community in Washington State. These insightful discussions were absolutely critical for contextualizing our results. We would also like to sincerely thank Kelsey Florek for locating and sharing mumps samples from Wisconsin, Ohio, Missouri, Alabama, and North Carolina, which greatly enhanced the analyses presented here. We also thank Jeff Joy for graciously sharing mumps genomes from British Columbia. Finally, we would like to thank the Fred Hutchinson Cancer Research Center sequencing core for providing excellent sequencing services and Fred Hutch Scientific Computing Infrastructure. LHM is an Open Philanthropy Project fellow of the Life Sciences Research Foundation. AB was supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE-1256082. TB is a Pew Biomedical Scholar and is supported by NIH R35 GM119774-01. Scientific Computing Infrastructure at Fred Hutch is supported by NIH ORIP S10OD028685.

Author contributions

LHM and AB generated and analyzed data and wrote the manuscript. CD and NRG provided data and contributed to writing the manuscript. ML, APO, and SL, provided sample and support for the study. DH provided conceptual input and contributed to the writing of the manuscript. NFM analyzed data and helped write the manuscript. TB planned the study, supported data analysis, and wrote the manuscript.

Supplemental Figure 1: Mumps genomes accumulate mutations linearly over time

We inferred a maximum likelihood phylogeny using IQTREE for all available complete mumps genomes of genotype G, sampled from North America between 2006 and 2018. We inferred the root-to-tip distance with TempEst and plot the root to tip divergence vs. sample collection date. Color represents geographic location (either Canadian province or US state), with colors corresponding to those in Figure 2. We infer that mumps genomes accumulate mutations at a rate of 3.75×10^{-4} substitutions per site per year.

Supplemental Figure 2: SH gene sequences are inadequate for fine-scale resolution of mumps transmission

a. We inferred a maximum likelihood phylogeny using IQTREE for all available complete mumps genomes of genotype G, sampled from North America between 2006 and 2018. Color represents geographic location (either Canadian province or US state), and the x-axis displays divergence in substitutions per site per year. **b.** To compare whether similar results would have been obtained if we had only sequenced the SH gene, we truncated our sequences to include only the coding region for SH and again inferred a maximum likelihood phylogeny using the same procedure as in a. The vast majority of North American mumps sequences are identical and form a single polytomy, suggesting that SH sequencing alone provides limited resolution for inferring geographic spread.

Supplemental Figure 3: Rarefaction results by vaccination status

We repeated the rarefaction analysis shown in Figure 4b for vaccination status. We separated all Washington tips and classified them by vaccination status into up-to-date, not up-to-date, or unknown vaccination status. We then performed a rarefaction analysis and plot the number of inferred Washington clusters (y-axis) as a function of the number of sequences included in the analysis (x-axis). Dark green represents unknown vaccination status, light green represents not up-to-date, and green represents up-to-date. The majority of sequences in our dataset were derived from individuals who were up-to-date for mumps vaccine. Each dot represents the number of trials in which that number of clusters was inferred, and the solid line represents the mean across trials.

Supplemental Figure 4: Inferences are similar under a higher migration rate prior

The results are shown for the exact same analyses displayed in Figure 5, except inferred under a model with a higher migration rate prior (10 instead of 1). **a.** Using the 4 Washington clusters that had a mixture of Marshallese and non-Marshallese cases, we inferred phylogenies using a structured coalescent model. Each group of sequences shared a clock model, migration model, and substitution model, but each topology was inferred separately, allowing us to incorporate information from all 4 clusters into the migration estimation. For each cluster, the maximum clade credibility tree is shown, where the color of each internal node represents the posterior probability that the node is Marshallese. **b.** For each internal node shown in panel **a**, we plot the posterior probability of that node being Marshallese. Across all 4 clusters, almost every internal node is inferred as Marshallese with high probability. **c.** The posterior distribution of the number of “jumps” or transmission events from Marshallese to not Marshallese (light blue) and not Marshallese to Marshallese (dark blue) inferred for the primary outbreak clade.

Supplemental Figure 5: Structured coalescent analyses are robust to sampling differences

To ensure that our results were robust to differences in sampling of Marshallese and non-Marshallese tips within the clusters used for this analysis, we subsampled our dataset 3 independent times, and ran 3 independent chains per unique subsampling. In each subsampled dataset, the number of Marshallese tips was randomly subsampled to be equal to the number of non-Marshallese tips in each of the 4 clusters. We then ran each of these subsampled datasets with the exact same model as run with the full dataset. In subsampled datasets 1 and 2, 2 out of 3 chains converged, and results were combined and displayed here. In the 3rd subsampled dataset, none of the 3 chains converged, so those results are not shown. **a.** For each subsampled dataset, we plot the inferred maximum clade credibility tree from the combined tree outputs from the 2 converged chains. The color of each tip represents whether that sample was derived from a Marshallese or non-Marshallese case, and the color of the internal node represents the posterior probability of that internal node being Marshallese. **b.** For each tree shown in **a**, the posterior probability that each internal node is labelled as Marshallese is shown. The number of the subsampled dataset is shown on the x-axis and the posterior probability is shown on the y-axis.

Supplemental Figure 6: Including all Washington sequences recovers majority of transmission in Marshallese

To ensure that excluding non-Marshallese clusters did not skew our findings, we inferred a single tree using all Washington sequences. We performed a structured coalescent analysis specifying 3 groups: Marshallese, not Marshallese, and not Washington. Each internal node is colored by its most probable group, with its opacity specifying the posterior probability of being in that group (fully opaque being probability = 1, fully transparent being probability = 0).

a

b

Supplemental Figure 7: Posterior probabilities of internal node states

a. For the tree shown in Supplemental Figure 6, each internal node is plotted. For each internal node, its color and placement on the x-axis represents its inferred most probable group (Marshallese, Not Marshallese, or Not Washington). The posterior probability of being labelled its most probable group is shown on the y-axis. We recover moderate support for a small number of non-Marshallese internal nodes, while the vast majority of internal nodes remain inferred as Marshallese. **b.** The 95% highest posterior density intervals of the inferred effective population sizes for Marshallese, non-Marshallese, and not Washington demes.

Supplemental Table 1: Sample metadata

Strain name	Sample type	Country	US state	Mumps genotype	Vaccination status	Cycle threshold (Ct)	Genome coverage
MuVs/Washington.USA/48.16/FH1[G]	Buccal Swab	USA	Washington	G	up-to-date	29.32	0.91
MuVs/Washington.USA/50.16/FH2[G]	Buccal Swab	USA	Washington	G	up-to-date	25.11	0.93
MuVs/Washington.USA/50.16/FH3[G]	Buccal Swab	USA	Washington	G	up-to-date	28.53	0.84
MuVs/Washington.USA/50.16/FH4[G]	Buccal Swab	USA	Washington	G	unknown	27.51	0.84
MuVs/Washington.USA/1.17/FH5[G]	Buccal Swab	USA	Washington	G	up-to-date	23.04	0.93
MuVs/Washington.USA/1.17/FH6[G]	Buccal Swab	USA	Washington	G	not up-to-date	32.87	0.93
MuVs/Washington.USA/1.17/FH7[G]	Buccal Swab	USA	Washington	G	up-to-date	25.29	0.92
MuVs/Washington.USA/1.17/FH8[G]	Buccal Swab	USA	Washington	G	unknown	26.61	0.93
MuVs/Washington.USA/5.17/FH9[G]	Buccal Swab	USA	Washington	G	up-to-date	30.38	0.84
MuVs/Washington.USA/5.17/FH10[G]	Buccal Swab	USA	Washington	G	up-to-date	26.72	0.92
MuVs/Washington.USA/5.17/FH11[G]	Buccal Swab	USA	Washington	G	up-to-date	28.17	0.93
MuVs/Washington.USA/6.17/FH12[G]	Buccal Swab	USA	Washington	G	unknown	25.00	0.93

MuVs/Washington.USA/6.17/FH13[G]	Buccal Swab	USA	Washington	G	up-to-date	25.31	0.93
MuVs/Washington.USA/6.17/FH14[G]	Buccal Swab	USA	Washington	G	unknown	29.04	0.93
MuVs/Washington.USA/7.17/FH15[G]	Buccal Swab	USA	Washington	G	unknown	33.33	0.92
MuVs/Washington.USA/9.17/FH16[G]	Buccal Swab	USA	Washington	G	up-to-date	23.17	0.93
MuVs/Washington.USA/8.17/FH17[G]	Buccal Swab	USA	Washington	G	up-to-date	28.83	0.92
MuVs/Washington.USA/9.17/FH18[G]	Buccal Swab	USA	Washington	G	up-to-date	31.84	0.84
MuVs/Washington.USA/8.17/FH19[G]	Buccal Swab	USA	Washington	G	unknown	32.16	0.93
MuVs/Washington.USA/15.17/FH20[G]	Buccal Swab	USA	Washington	G	up-to-date	22.25	0.93
MuVs/Washington.USA/2.17/FH21[G]	Buccal Swab	USA	Washington	G	up-to-date	26.50	0.92
MuVs/Washington.USA/2.17/FH22[G]	Buccal Swab	USA	Washington	G	not up-to-date	31.09	0.85
MuVs/Washington.USA/2.17/FH23[G]	Buccal Swab	USA	Washington	G	up-to-date	25.61	0.92
MuVs/Washington.USA/3.17/FH24[G]	Buccal Swab	USA	Washington	G	up-to-date	21.89	0.93
MuVs/Washington.USA/3.17/FH25[G]	Buccal Swab	USA	Washington	G	up-to-date	27.23	0.93
MuVs/Washington.USA/2.17/FH26[G]	Buccal	USA	Washington	G	up-to-date	29.08	0.93

	Swab						
MuVs/Washington.USA/5.17/FH27[G]	Buccal Swab	USA	Washington	G	up-to-date	24.53	0.93
MuVs/Washington.USA/52.16/FH28[G]	Buccal Swab	USA	Washington	G	unknown	34.28	0.74
MuVs/Washington.USA/1.17/FH29[G]	Buccal Swab	USA	Washington	G	up-to-date	33.14	0.64
MuVs/Washington.USA/5.17/FH30[G]	Buccal Swab	USA	Washington	G	unknown	33.27	0.63
MuVs/Washington.USA/9.17/FH31[G]	Buccal Swab	USA	Washington	G	up-to-date	34.94	0.66
MuVs/Washington.USA/30.17/FH32[G]	Buccal Swab	USA	Washington	G	not up-to-date	21.88	0.93
MuVs/Washington.USA/50.16/FH33[G]	Buccal Swab	USA	Washington	G	unknown	23.94	0.92
MuVs/Washington.USA/12.17/FH34[G]	Buccal Swab	USA	Washington	G	up-to-date	24.15	0.93
MuVs/Washington.USA/12.17/FH35[G]	Buccal Swab	USA	Washington	G	not up-to-date	28.12	0.93
MuVs/Washington.USA/16.17/FH36[G]	Buccal Swab	USA	Washington	G	up-to-date	25.15	0.93
MuVs/Washington.USA/17.17/FH37[G]	Buccal Swab	USA	Washington	G	unknown	25.71	0.93
MuVs/Washington.USA/17.17/FH38[G]	Buccal Swab	USA	Washington	G	unknown	26.45	0.93
MuVs/Washington.USA/17.17/FH39[G]	Buccal Swab	USA	Washington	G	up-to-date	26.69	0.93

MuVs/Washington.USA/17.17/FH40[G]	Buccal Swab	USA	Washington	G	up-to-date	21.78	0.93
MuVs/Washington.USA/51.16/FH41[G]	Buccal Swab	USA	Washington	G	unknown	23.56	0.93
MuVs/Washington.USA/9.17/FH42[G]	Buccal Swab	USA	Washington	G	up-to-date	23.29	0.93
MuVs/Washington.USA/10.17/FH43[G]	Buccal Swab	USA	Washington	G	up-to-date	24.50	1.00
MuVs/Washington.USA/19.17/FH44[G]	Buccal Swab	USA	Washington	G	unknown	27.26	0.93
MuVs/Washington.USA/49.16/FH45[G]	Buccal Swab	USA	Washington	G	unknown	30.24	0.93
MuVs/Washington.USA/51.16/FH46[G]	Buccal Swab	USA	Washington	G	unknown	25.69	0.93
MuVs/Washington.USA/2.17/FH47[G]	Buccal Swab	USA	Washington	G	up-to-date	24.04	0.93
MuVs/Washington.USA/4.17/FH48[G]	Buccal Swab	USA	Washington	G	up-to-date	20.15	0.93
MuVs/Washington.USA/4.17/FH49[G]	Buccal Swab	USA	Washington	G	up-to-date	31.31	0.93
MuVs/Washington.USA/5.17/FH50[G]	Buccal Swab	USA	Washington	G	unknown	31.14	0.85
MuVs/Washington.USA/6.17/FH51[G]	Buccal Swab	USA	Washington	G	unknown	26.59	0.92
MuVs/Washington.USA/10.17/FH52[G]	Buccal Swab	USA	Washington	G	not up-to-date	23.76	0.93
MuVs/Washington.USA/19.17/FH53[G]	Buccal	USA	Washington	G	unknown	22.25	0.93

G]	Swab						
MuVs/Washington.USA/2.17/FH54[G]	Buccal Swab	USA	Washington	G	up-to-date	24.47	0.84
MuVs/Washington.USA/49.16/FH55[G]	nasopharyngeal/throat swab	USA	Washington	G	unknown	28.39	0.84
MuVs/Washington.USA/11.17/FH56[G]	Buccal Swab	USA	Washington	G	unknown	25.31	1.00
MuVs/Washington.USA/12.17/FH57[G]	Buccal Swab	USA	Washington	G	unknown	32.79	0.93
MuVs/Washington.USA/2.17/FH58[G]	Buccal Swab	USA	Washington	G	up-to-date	23.20	0.93
MuVs/Washington.USA/3.17/FH59[G]	Buccal Swab	USA	Washington	G	up-to-date	26.24	0.93
MuVs/Washington.USA/4.17/FH60[G]	Buccal Swab	USA	Washington	G	not up-to-date	26.87	0.93
MuVs/Washington.USA/7.17/FH61[G]	Buccal Swab	USA	Washington	G	unknown	24.86	0.98
MuVs/Washington.USA/3.17/FH62[G]	Buccal Swab	USA	Washington	G	unknown	26.99	0.94
MuVs/Washington.USA/16.17/FH63[G]	Buccal Swab	USA	Washington	G	up-to-date	24.26	0.99
MuVs/Washington.USA/50.16/FH64[G]	Buccal Swab	USA	Washington	G	up-to-date	34.54	0.93
MuVs/Washington.USA/1.17/FH65[G]	Buccal Swab	USA	Washington	G	up-to-date	28.53	0.93
MuVs/Washington.USA/2.17/FH66[G]	Buccal	USA	Washington	G	unknown	23.51	0.93

	Swab						
MuVs/Washington.USA/3.17/FH67[G]	Buccal Swab	USA	Washington	G	up-to-date	29.70	0.93
MuVs/Washington.USA/4.17/FH68[G]	Buccal Swab	USA	Washington	G	up-to-date	27.07	0.93
MuVs/Washington.USA/21.17/FH69[G]	Buccal Swab	USA	Washington	G	not up-to-date	22.46	0.93
MuVs/Washington.USA/4.17/FH70[G]	Buccal Swab	USA	Washington	G	unknown	25.32	0.93
MuVs/Washington.USA/4.17/FH71[G]	Buccal Swab	USA	Washington	G	up-to-date	25.92	0.93
MuVs/Washington.USA/5.17/FH72[G]	Buccal Swab	USA	Washington	G	unknown	22.74	0.93
MuVs/Washington.USA/20.17/FH73[G]	Buccal Swab	USA	Washington	G	up-to-date	28.59	0.93
MuVs/Washington.USA/22.17/FH74[G]	Buccal Swab	USA	Washington	G	up-to-date	28.84	0.93
MuVs/Washington.USA/52.16/FH75[G]	Buccal Swab	USA	Washington	G	up-to-date	27.02	0.93
MuVs/Washington.USA/12.17/FH76[G]	Buccal Swab	USA	Washington	G	not up-to-date	25.15	0.93
MuVs/Washington.USA/1.17/FH77[G]	Buccal Swab	USA	Washington	G	up-to-date	34.73	0.92
MuVs/Washington.USA/12.17/FH78[G]	Buccal Swab	USA	Washington	G	unknown	27.05	0.90
MuVs/Washington.USA/16.17/FH79[G]	Buccal Swab	USA	Washington	G	up-to-date	27.44	0.93

MuVs/Washington.USA/19.17/FH80[G]	Buccal Swab	USA	Washington	G	unknown	29.00	0.93
MuVs/Washington.USA/20.17/FH81[G]	Buccal Swab	USA	Washington	G	not up-to-date	27.85	0.93
MuVs/Washington.USA/20.17/FH82[G]	Buccal Swab	USA	Washington	G	up-to-date	33.04	0.84
MuVs/Washington.USA/29.17/FH83[G]	Buccal Swab	USA	Washington	G	not up-to-date	32.28	0.93
MuVs/Washington.USA/2.17/FH84[G]	Buccal Swab	USA	Washington	G	not up-to-date	23.08	0.84
MuVs/Wisconsin.USA/16.14/FH85[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.76
MuVs/Wisconsin.USA/20.14/FH86[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.58
MuVs/Wisconsin.USA/15.06/FH87[H]	unknown	USA	Wisconsin	H	unknown	unknown	0.53
MuVs/Missouri.USA/32.16/FH88[G]	unknown	USA	Missouri	G	unknown	unknown	0.78
MuVs/Wisconsin.USA/15.17/FH89[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.78
MuVs/Alabama.USA/11.17/FH90[G]	unknown	USA	Alabama	G	unknown	unknown	0.80
MuVs/Wisconsin.USA/15.06/FH91[A]	unknown	USA	Wisconsin	A	unknown	unknown	0.71
MuVs/Alabama.USA/19.17/FH92[G]	unknown	USA	Alabama	G	unknown	unknown	0.77
MuVs/Wisconsin.USA/37.06/FH93[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.69
MuVs/Washington.USA/9.17/FH94[K]	Buccal Swab	USA	Washington	K	unknown	29.13	0.63
MuVs/Washington.USA/11.17/FH95[G]	Buccal Swab	USA	Washington	G	up-to-date	28.52	0.77
MuVs/Washington.USA/11.17/FH96[G]	Buccal Swab	USA	Washington	G	up-to-date	36.91	0.76

MuVs/Washington.USA/12.17/FH97[G]	Buccal Swab	USA	Washington	G	up-to-date	35.13	0.63
MuVs/Washington.USA/14.17/FH98[G]	Buccal Swab	USA	Washington	G	not up-to-date	29.59	0.76
MuVs/Wisconsin.USA/41.06/FH99[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.77
MuVs/Washington.USA/19.17/FH100[G]	Buccal Swab	USA	Washington	G	up-to-date	29.44	0.78
MuVs/Missouri.USA/28.17/FH101[G]	unknown	USA	Missouri	G	unknown	unknown	0.80
MuVs/Ohio.USA/2.18/FH102[G]	unknown	USA	Ohio	G	unknown	unknown	0.76
MuVs/Washington.USA/4.17/FH103[G]	Buccal Swab	USA	Washington	G	up-to-date	34.19	0.56
MuVs/Washington.USA/5.17/FH104[G]	Buccal Swab	USA	Washington	G	up-to-date	31.96	0.74
MuVs/Washington.USA/6.17/FH105[G]	Buccal Swab	USA	Washington	G	up-to-date	36.53	0.65
MuVs/Washington.USA/7.17/FH106[G]	Buccal Swab	USA	Washington	G	not up-to-date	27.98	0.67
MuVs/Wisconsin.USA/7.07/FH107[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.80
MuVs/Wisconsin.USA/11.07/FH108[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94
MuVs/Wisconsin.USA/11.07/FH109[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94
MuVs/Wisconsin.USA/16.14/FH110[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.92
MuVs/Wisconsin.USA/20.14/FH111[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94

MuVs/Wisconsin.USA/24.14/FH112[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.87
MuVs/Wisconsin.USA/29.14/FH113[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.93
MuVs/Missouri.USA/29.15/FH114[G]	unknown	USA	Missouri	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/42.15/FH115[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.87
MuVs/Wisconsin.USA/42.15/FH116[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.88
MuVs/Wisconsin.USA/46.15/FH117[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/2.16/FH118[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.91
MuVs/Ohio.USA/19.16/FH119[G]	unknown	USA	Ohio	G	unknown	unknown	0.93
MuVs/Wisconsin.USA/24.16/FH120[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.89
MuVs/Wisconsin.USA/19.16/FH121[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.93
MuVs/Missouri.USA/41.16/FH122[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Missouri.USA/46.16/FH123[G]	unknown	USA	Missouri	G	unknown	unknown	0.88
MuVs/Missouri.USA/46.16/FH124[G]	unknown	USA	Missouri	G	unknown	unknown	0.90
MuVs/Missouri.USA/50.16/FH125[G]	unknown	USA	Missouri	G	unknown	unknown	0.88
MuVs/Wisconsin.USA/50.16/FH126[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.88
MuVs/Missouri.USA/2.17/FH127[G]	unknown	USA	Missouri	G	unknown	unknown	0.83
MuVs/Ohio.USA/2.17/FH128[G]	unknown	USA	Ohio	G	unknown	unknown	0.90

MuVs/Missouri.USA/7.17/FH129[G]	unknown	USA	Missouri	G	unknown	unknown	0.84
MuVs/Ohio.USA/7.17/FH130[G]	unknown	USA	Ohio	G	unknown	unknown	0.89
MuVs/Wisconsin.USA/15.06/FH131[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.81
MuVs/Ohio.USA/11.17/FH132[G]	unknown	USA	Ohio	G	unknown	unknown	0.86
MuVs/Missouri.USA/11.17/FH133[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Missouri.USA/15.17/FH134[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Missouri.USA/15.17/FH135[G]	unknown	USA	Missouri	G	unknown	unknown	0.86
MuVs/NorthCarolina.USA/11.17/FH136[G]	unknown	USA	NorthCarolina	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/15.17/FH137[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.85
MuVs/Missouri.USA/15.17/FH138[G]	unknown	USA	Missouri	G	unknown	unknown	0.82
MuVs/Alabama.USA/15.17/FH139[G]	unknown	USA	Alabama	G	unknown	unknown	0.83
MuVs/Missouri.USA/19.17/FH140[G]	unknown	USA	Missouri	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/19.17/FH141[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.85
MuVs/Washington.USA/8.17/FH142[G]	Buccal Swab	USA	Washington	G	up-to-date	25.33	0.86
MuVs/Washington.USA/11.17/FH143[G]	Buccal Swab	USA	Washington	G	up-to-date	28.34	0.87
MuVs/Washington.USA/12.17/FH144[G]	Buccal Swab	USA	Washington	G	unknown	29.66	0.85
MuVs/Washington.USA/14.17/FH145[G]	Buccal Swab	USA	Washington	G	up-to-date	21.45	0.91

MuVs/Washington.USA/15.17/FH146[G]	Buccal Swab	USA	Washington	G	up-to-date	27.09	0.84
MuVs/Washington.USA/18.17/FH147[G]	Buccal Swab	USA	Washington	G	up-to-date	28.86	0.88
MuVs/Washington.USA/20.17/FH148[G]	Buccal Swab	USA	Washington	G	up-to-date	26.59	0.82
MuVs/Washington.USA/23.17/FH149[G]	Buccal Swab	USA	Washington	G	unknown	33.05	0.84
MuVs/Washington.USA/23.17/FH150[G]	Buccal Swab	USA	Washington	G	up-to-date	32.33	0.84
MuVs/Washington.USA/28.17/FH151[G]	Buccal Swab	USA	Washington	G	up-to-date	24.18	0.88
MuVs/Washington.USA/16.17/FH152[G]	Buccal Swab	USA	Washington	G	up-to-date	27.41	0.85
MuVs/Wisconsin.USA/41.06/FH153[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/7.07/FH154[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94
MuVs/Missouri.USA/33.17/FH155[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Alabama.USA/50.17/FH156[G]	unknown	USA	Alabama	G	unknown	unknown	0.85
MuVs/Ohio.USA/46.17/FH157[G]	unknown	USA	Ohio	G	unknown	unknown	0.84
MuVs/Washington.USA/49.16/FH158[G]	Buccal Swab	USA	Washington	G	unknown	30.55	0.84
MuVs/Wisconsin.USA/28.06/FH159[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.84
MuVs/Washington.USA/1.17/FH160[G]	Buccal Swab	USA	Washington	G	unknown	24.17	0.87

MuVs/Washington.USA/5.17/FH161[G]	Buccal Swab	USA	Washington	G	up-to-date	23.05	0.92
MuVs/Washington.USA/5.17/FH162[G]	Buccal Swab	USA	Washington	G	up-to-date	27.08	0.90
MuVs/Wisconsin.USA/51.15/FH163[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.86
MuVs/Alabama.USA/7.17/FH164[G]	unknown	USA	Alabama	G	unknown	unknown	0.80
MuVs/Missouri.USA/24.17/FH165[G]	unknown	USA	Missouri	G	unknown	unknown	0.86
MuVs/Washington.USA/7.17/FH166[G]	Buccal Swab	USA	Washington	G	up-to-date	27.96	0.85

All genomes generated for this analysis are described above. Dates are formatted as Year-month-day. Vaccination status, Ct, and sample collection type are all available for the Washington samples. Genome coverage represents the total proportion of bases in the genome with at least 20x coverage for which we were able to call a base. Sites with <20x coverage were labelled as Ns. Only samples with at least 50% non-N bases were included in the analysis.

Supplemental Table 2: Mumps cases by age group

Age group	Mumps case count	2016-2017 average population in Washington ¹	Rate of cases per 100,000 individuals	Percentage of total cases
0 - 4	34	450,847	7.5	3.8%
5 - 9	104	462,951	22.5	11.7%
10 - 14	198	451,485	43.9	22.3%
15 - 19	214	455,612	47.0	24.1%
20 - 39	256	1,980,004	12.9	28.8%

40 - 64	80	2,348,529.5	3.4	10.0%
65+	2	1,097,571	0.2	0.22%
Unknown	1	NA	NA	0.11%

Supplemental Table 3: Outbreak characteristic and dataset composition

	counts in outbreak (%)	Count in dataset (%)
Up-to-date vaccination	574 (65%)	64 (58%)
Not up-to-date vaccination	86 (9.7%)	13 (12%)
Unknown vaccination status	229 (26%)	33 (30%)
Marshallese	465 (52%)	57 (52%)
Not Marshallese	424 (48%)	53 (48%)
Total	889	110

Supplemental References

1. Estimates of April 1 population by age, sex, race and Hispanic origin. <https://www.ofm.wa.gov/washington-data-research/population-demographics/population-estimates/estimates-april-1-population-age-sex-race-and-hispanic-origin.s>